<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Topiramate add‐on therapy for drug‐resistant focal epilepsy - Bresnahan, R - 2019 | Cochrane Library</title> <meta content="Topiramate add‐on therapy for drug‐resistant focal epilepsy - Bresnahan, R - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001417.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Topiramate add‐on therapy for drug‐resistant focal epilepsy - Bresnahan, R - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001417.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001417.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Topiramate add‐on therapy for drug‐resistant focal epilepsy" name="citation_title"/> <meta content="Rebecca Bresnahan" name="citation_author"/> <meta content="Institute of Translational Medicine, University of Liverpool" name="citation_author_institution"/> <meta content="rebecca.bresnahan@liverpool.ac.uk" name="citation_author_email"/> <meta content="Juliet Hounsome" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="Nathalie Jette" name="citation_author"/> <meta content="Icahn School of Medicine at Mount Sinai" name="citation_author_institution"/> <meta content="Jane L Hutton" name="citation_author"/> <meta content="University of Warwick" name="citation_author_institution"/> <meta content="Anthony G Marson" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD001417.pub4" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/10/23" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001417.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001417.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001417.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Drug Resistance; Anticonvulsants [*therapeutic use]; Epilepsies, Partial [*drug therapy]; Fructose [*analogs &amp; derivatives, therapeutic use]; Randomized Controlled Trials as Topic; Topiramate; Treatment Failure" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001417.pub4&amp;doi=10.1002/14651858.CD001417.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001417.pub4&amp;doi=10.1002/14651858.CD001417.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001417.pub4&amp;doi=10.1002/14651858.CD001417.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001417.pub4&amp;doi=10.1002/14651858.CD001417.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001417.pub4&amp;doi=10.1002/14651858.CD001417.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001417.pub4&amp;doi=10.1002/14651858.CD001417.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001417.pub4&amp;doi=10.1002/14651858.CD001417.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001417.pub4&amp;doi=10.1002/14651858.CD001417.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001417.pub4&amp;doi=10.1002/14651858.CD001417.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001417.pub4&amp;doi=10.1002/14651858.CD001417.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001417.pub4&amp;doi=10.1002/14651858.CD001417.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001417.pub4&amp;doi=10.1002/14651858.CD001417.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001417.pub4&amp;doi=10.1002/14651858.CD001417.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001417.pub4&amp;doi=10.1002/14651858.CD001417.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001417.pub4&amp;doi=10.1002/14651858.CD001417.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001417.pub4&amp;doi=10.1002/14651858.CD001417.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001417.pub4&amp;doi=10.1002/14651858.CD001417.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001417.pub4&amp;doi=10.1002/14651858.CD001417.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001417.pub4&amp;doi=10.1002/14651858.CD001417.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001417.pub4&amp;doi=10.1002/14651858.CD001417.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001417.pub4&amp;doi=10.1002/14651858.CD001417.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001417.pub4&amp;doi=10.1002/14651858.CD001417.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001417.pub4&amp;doi=10.1002/14651858.CD001417.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="1ljSZou6";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001417\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001417\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001417\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001417\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","fa","fr","ru"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001417.pub4",title:"Topiramate add\\u2010on therapy for drug\\u2010resistant focal epilepsy",firstPublishedDate:"Oct 23, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Epilepsy Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001417.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001417.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001417.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001417.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001417.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001417.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001417.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001417.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001417.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001417.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2111 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001417.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001417.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001417.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001417.pub4/full#CD001417-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001417.pub4/full#CD001417-sec-0094"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001417.pub4/full#CD001417-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001417.pub4/full#CD001417-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001417.pub4/full#CD001417-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001417.pub4/full#CD001417-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001417.pub4/full#CD001417-sec-0068"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001417.pub4/full#CD001417-sec-0088"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001417.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001417.pub4/appendices#CD001417-sec-0099"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001417.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001417.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/table_n/CD001417StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/table_n/CD001417StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001417.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001417.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001417.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001417.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001417.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001417.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Topiramate add‐on therapy for drug‐resistant focal epilepsy</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001417.pub4/information#CD001417-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Rebecca Bresnahan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001417.pub4/information#CD001417-cr-0003">Juliet Hounsome</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001417.pub4/information#CD001417-cr-0004">Nathalie Jette</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001417.pub4/information#CD001417-cr-0005">Jane L Hutton</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001417.pub4/information#CD001417-cr-0006">Anthony G Marson</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/information/en#CD001417-sec-0108">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 23 October 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001417.pub4">https://doi.org/10.1002/14651858.CD001417.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001417-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001417-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001417-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001417-abs-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001417-abs-0003">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001417-abs-0001" lang="en"> <section id="CD001417-sec-0001"> <h3 class="title" id="CD001417-sec-0001">Background</h3> <p>The majority of people with epilepsy have a good prognosis and their seizures are controlled by a single antiepileptic drug. However, up to 20% of patients from population‐based studies, and up to 30% from clinical series (not population‐based), develop drug‐resistant epilepsy, especially those with focal‐onset seizures. In this review, we summarise the current evidence regarding topiramate, an antiepileptic drug first marketed in 1996, when used as an add‐on treatment for drug‐resistant focal epilepsy. </p> <p>This is an update of a Cochrane Review first published in 1999, and last updated in 2014. </p> </section> <section id="CD001417-sec-0002"> <h3 class="title" id="CD001417-sec-0002">Objectives</h3> <p>To evaluate the efficacy and tolerability of topiramate when used as an add‐on treatment for people with drug‐resistant focal epilepsy. </p> </section> <section id="CD001417-sec-0003"> <h3 class="title" id="CD001417-sec-0003">Search methods</h3> <p>For the latest update of this review we searched the following databases on 2 July 2018: Cochrane Register of Studies (CRS Web), which includes the Cochrane Epilepsy Group Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL); MEDLINE (Ovid, 1946‐ ); <a href="https://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> and the <a href="http://apps.who.int/trialsearch/" target="_blank">WHO International Clinical Trials Registry Platform</a> (ICTRP). We imposed no language restrictions. We also contacted the manufacturers of topiramate and researchers in the field to identify any ongoing or unpublished studies. </p> </section> <section id="CD001417-sec-0004"> <h3 class="title" id="CD001417-sec-0004">Selection criteria</h3> <p>Randomised, placebo‐controlled add‐on trials of topiramate, recruiting people with drug‐resistant focal epilepsy. </p> </section> <section id="CD001417-sec-0005"> <h3 class="title" id="CD001417-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected trials for inclusion and extracted the relevant data. We assessed the following outcomes: (1) 50% or greater reduction in seizure frequency; (2) seizure freedom; (3) treatment withdrawal (any reason); (4) adverse effects. Primary analyses were intention‐to‐treat (ITT), and summary risk ratios (RRs) with 95% confidence intervals (95% CIs) are presented. We evaluated dose‐response in regression models. We carried out a 'Risk of bias' assessment for each included study using the Cochrane 'Risk of bias' tool and assessed the overall certainty of evidence using the GRADE approach. </p> </section> <section id="CD001417-sec-0006"> <h3 class="title" id="CD001417-sec-0006">Main results</h3> <p>We included 12 trials, representing 1650 participants. Baseline phases ranged from four to 12 weeks and double‐blind phases ranged from 11 to 19 weeks. The RR for a 50% or greater reduction in seizure frequency with add‐on topiramate compared to placebo was 2.71 (95% CI 2.05 to 3.59; 12 studies; high‐certainty evidence). Dose regression analysis showed increasing effect with increasing topiramate dose demonstrated by an odds ratio (OR) of 1.45 (95% CI 1.28 to 1.64; P &lt; 0.001) per 200 mg/d increase in topiramate dosage. The proportion of participants achieving seizure freedom was also significantly increased with add‐on topiramate compared to placebo (RR 3.67, 95% CI 1.79 to 7.54; 8 studies; moderate‐certainty evidence). Treatment withdrawal was significantly higher for add‐on topiramate compared to placebo (RR 2.37, 95% CI 1.66 to 3.37; 12 studies; high‐certainty evidence). The RRs for the following adverse effects indicate that they are significantly more prevalent with topiramate, compared to placebo: ataxia 2.29 (99% CI 1.10 to 4.77; 4 studies); concentration difficulties 7.81 (99% CI 2.08 to 29.29; 6 studies; moderate‐certainty evidence); dizziness 1.52 (99% CI 1.07 to 2.16; 8 studies); fatigue 2.08 (99% CI 1.37 to 3.15; 10 studies); paraesthesia 3.65 (99% CI 1.58 to 8.39; 7 studies; moderate‐certainty evidence); somnolence 2.44 (99% CI 1.61 to 3.68; 9 studies); 'thinking abnormally' 5.70 (99% CI 2.26 to 14.38; 4 studies; high‐certainty evidence); and weight loss 3.99 (99% CI 1.82 to 8.72; 9 studies; low‐certainty evidence). Evidence of publication bias for the primary outcome was found (Egger test, P = 0.001). We rated all studies included in the review as having either low or unclear risk of bias. Overall, we assessed the evidence as moderate to high certainty due to the evidence of publication bias, statistical heterogeneity and imprecision, which was partially compensated for by large effect sizes. </p> </section> <section id="CD001417-sec-0007"> <h3 class="title" id="CD001417-sec-0007">Authors' conclusions</h3> <p>Topiramate has efficacy as an add‐on treatment for drug‐resistant focal epilepsy as it is almost three times more effective compared to a placebo in reducing seizures. The trials reviewed were of relatively short duration and provided no evidence for the long‐term efficacy of topiramate. Short‐term use of add‐on topiramate was shown to be associated with several adverse events. The results of this review should only be applied to adult populations as only one study included children. Future research should consider further examining the effect of dose. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001417-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001417-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001417-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001417-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001417-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001417-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD001417-abs-0010">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001417-abs-0005" lang="en"> <h3>Topiramate add‐on for drug‐resistant focal epilepsy</h3> <p><b>Background</b> </p> <p>Epilepsy is a disorder where recurrent seizures are caused by abnormal electrical discharges from the brain. Most seizures can be controlled by a single antiepileptic drug. Unfortunately, some people require more than one antiepileptic medication to control their seizures, especially if these originate from one area of the brain (focal epilepsy), instead of affecting the entire brain (generalised epilepsy). These people are said to have drug‐resistant epilepsy. Topiramate can be used in addition to other antiepileptic drugs, called an add‐on treatment, to try to control drug‐resistant epilepsy. </p> <p><b>Aim of this review</b> </p> <p>This review investigated the effectiveness and tolerability of topiramate when used as an add‐on treatment for people with drug‐resistant focal epilepsy. </p> <p><b>Results</b> </p> <p>We found 12 trials that investigated topiramate as an add‐on treatment. They included a total of 1650 people with drug‐resistant focal epilepsy. These trials compared the antiepileptic drug topiramate to a placebo drug (an inactive, dummy drug which should not show any effect) for a period of up to 18 weeks. Taking all the evidence of the trials into account, the review found that topiramate is almost three times more effective, when used with other drugs, at reducing the number of seizures in drug‐resistant focal epilepsy than placebo. Adding topiramate to people's usual treatment was, however, associated with an increase in adverse effects such as problems with co‐ordination (ataxia), concentration, dizziness, drowsiness (somnolence), fatigue, 'thinking abnormally', tickling or numbness of the skin (paraesthesia) and weight loss. People taking add‐on topiramate were also more than twice as likely to withdraw from treatment than those taking placebo, most likely due to adverse effects. </p> <p><b>Certainty of the evidence</b> </p> <p>We assessed the trials with regards to potential bias and certainty. Overall, we rated the certainty of the evidence as moderate to high which means that we are fairly certain that the findings that we have reported are accurate. The trials included in this review did not examine the long‐term effects of topiramate as an add‐on treatment and only one study investigated the use of add‐on topiramate in children. The findings should, therefore, only be applied to adults with drug‐resistant focal epilepsy. Future research should test which dose is most effective. </p> <p>The evidence is current to July 2018.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001417-sec-0094" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001417-sec-0094"></div> <h3 class="title" id="CD001417-sec-0095">Implications for practice</h3> <section id="CD001417-sec-0095"> <p>Topiramate has efficacy as an add‐on treatment for people with drug‐resistant focal epilepsy. A daily dose of 200 mg is the lowest dose tested in the trials included in this review, and this would seem a reasonable starting dose. The dose regression model implied additional benefit with increased dosage, however, the increase was fairly modest. It is likely that higher doses will result in greater issues with adverse effects. </p> </section> <h3 class="title" id="CD001417-sec-0096">Implications for research</h3> <section id="CD001417-sec-0096"> <p>To evaluate further the place of topiramate in the armamentarium of available antiepileptic drugs, further studies are required addressing the following. </p> <p> <ol id="CD001417-list-0013"> <li> <p>The long‐term effects of add‐on topiramate.</p> </li> <li> <p>How topiramate compares with other add‐on treatments in drug‐resistant focal epilepsy.</p> </li> <li> <p>The role of topiramate in childhood epilepsies.</p> </li> <li> <p>How topiramate compares with standard antiepileptic drugs, such as monotherapy for focal or generalised epilepsies. </p> </li> <li> <p>The dose‐response relationship with adverse effects.</p> </li> </ol> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001417-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001417-sec-0029"></div> <div class="table" id="CD001417-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Topiramate compared to placebo for drug‐resistant focal epilepsy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Add‐on topiramate compared to placebo for drug‐resistant focal epilepsy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patients or population:</b> people with drug‐resistant focal epilepsy<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> add‐on topiramate<br/> <b>Comparison:</b> add‐on placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI; Adverse effects: 99% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with topiramate</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>50% or greater reduction in seizure frequency (ITT analysis)</b> </p> <p>Follow‐up: range 11 to 19 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.71</b><br/> (2.05 to 3.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>1650</b><br/> (12 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b><sup>a,b,c,f,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Topiramate increases the proportion of participants attaining a 50% or greater reduction in seizure frequency. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>163 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>441 per 1000<br/> (333 to 584) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Seizure freedom</b> </p> <p>Follow‐up: range 11 to 19 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 3.67</b><br/> (1.79 to 7.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1177<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Topiramate likely increases the proportion of participants achieving seizure freedom.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1000<br/> (30 to 125) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment withdrawal</b> </p> <p>Follow‐up: range 11 to 19 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.37</b><br/> (1.66 to 3.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>1650</b><br/> (12 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b><sup>a,d,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Topiramate increases the incidence of treatment withdrawal.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>144 per 1000<br/> (101 to 204) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects ‐ weight loss/decrease</b> </p> <p>Follow‐up: range 11 to 18 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 3.99</b><br/> (1.82 to 8.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>1070</b><br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c,e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Topiramate may produce a large increase in the proportion of participants experiencing weight loss. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81 per 1000<br/> (37 to 177) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects ‐ paraesthesia</b> </p> <p>Follow‐up: range 11 to 18 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 3.65</b><br/> (1.58 to 8.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>1071</b><br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Topiramate likely increases the proportion of participants experiencing paraesthesia.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>91 per 1000<br/> (40 to 210) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects ‐ 'thinking abnormally'</b> </p> <p>Follow‐up: range 12 to 19 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 5.70</b><br/> (2.26 to 14.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>640</b><br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b><sup>a,d,g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Topiramate increases the proportion of participants reporting that they are 'thinking abnormally'. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>243 per 1000<br/> (96 to 614) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects ‐ difficulty with concentration/concentration impaired/concentration‐attention difficulties</b> </p> <p>Follow‐up: range 11 to 18 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 7.81</b><br/> (2.08 to 29.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>702</b><br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,c,e,g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Topiramate likely increases the number of participants who experience difficulty with concentration. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88 per 1000<br/> (23 to 330) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% or 99% confidence interval, dependent on the outcome) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% or 99% CI, dependent on the outcome).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We did not downgrade evidence for risk of bias; we judged risk of bias across studies to be low. Ten studies did not describe the blinding of outcome assessors, one study failed to explain randomisation and allocation concealment and another did not describe any method of blinding. We, however, reasoned that the blinding of outcome assessors would minimally impact the estimated effect size due to the self‐reported nature of the review outcomes.<br/> <sup>b</sup>We downgraded the evidence once for inconsistency: we detected significant statistical heterogeneity.<br/> <sup>c</sup>We downgraded the evidence once for publication bias: examination of funnel plot and Egger test indicates the possibility of publication bias.<br/> <sup>d</sup>We downgraded the evidence once for imprecision: the number of events (&lt; 400) did not suffice optimal information size.<br/> <sup>e</sup>We downgraded the evidence twice for imprecision: the number of events (&lt; 100) did not suffice optimal information size.<br/> <sup>f</sup>We upgraded the evidence once for large effect: RR &gt; 2.00.<br/> <sup>g</sup>We upgraded the evidence twice for large effect: RR &gt; 5.00.<br/> <sup>h</sup>We upgraded the evidence once for dose‐response gradient: logistic regression demonstrated a significant dose‐response relationship. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001417-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001417-sec-0030"></div> <p>This is an update of a Cochrane Review first published in 1999 (<a href="./references#CD001417-bbs2-0040" title="JetteNJ , MarsonAG , KadirZA , HuttonJL . TOPIRAMATE IN DRUG‐RESISTANT PARTIAL EPILEPSY. Cochrane Database of Systematic Reviews1999, Issue 3. [DOI: 10.1002/14651858.CD001417] ">Jette 1999b</a>), and last updated in 2014 (<a href="./references#CD001417-bbs2-0046" title="PulmanJ , JetteN , DykemanJ , HemmingK , HuttonJL , MarsonAG . Topiramate add‐on for drug‐resistant partial epilepsy. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD001417.pub3] ">Pulman 2014</a>). The purpose of this update is to synthesise the current data in order to understand the role of topiramate as an add‐on treatment in drug‐resistant focal epilepsy. For the purpose of this review, people with drug‐resistant focal epilepsy have been defined as having focal‐onset seizures (simple focal and/or complex focal seizures and/or secondary generalised tonic‐clonic seizures) that have failed to respond to at least one monotherapy treatment with a standard antiepileptic drug. </p> <section id="CD001417-sec-0031"> <h3 class="title" id="CD001417-sec-0031">Description of the condition</h3> <p>The majority of people given a diagnosis of epilepsy have a good prognosis and their seizures are controlled by treatment with a single antiepileptic drug (<a href="./references#CD001417-bbs2-0029" title="KwanP , BrodieMJ . Early identification of refractory epilepsy. New England Journal of Medicine2000;342(5):314‐9. [DOI: 10.1056/NEJM200002033420503; PUBMED: 10660394] ">Kwan 2000</a>; <a href="./references#CD001417-bbs2-0035" title="ReynoldsEH , ShorvonSD , GalbraithAW , ChadwickD , DellaportasCI , VydelingumL . Phenytoin for epilepsy: a long term prospective study, assisted by serum level monitoring, in previously untreated patients. Epilepsia1981;22(4):475‐88. [PUBMED: 6790274] ">Reynolds 1981</a>), but up to 20% of patients from population‐based studies, and up to 30% from clinical (non population‐based) series, will develop drug‐resistant epilepsy (<a href="./references#CD001417-bbs2-0021" title="CockerellOC , JohnsonAL , SanderJW , HartYM , ShorvonSD . Remission of epilepsy: results from the national general practice study of epilepsy. Lancet1995;346(8968):140‐4. [PUBMED: 7603228] ">Cockerell 1995</a>; <a href="./references#CD001417-bbs2-0029" title="KwanP , BrodieMJ . Early identification of refractory epilepsy. New England Journal of Medicine2000;342(5):314‐9. [DOI: 10.1056/NEJM200002033420503; PUBMED: 10660394] ">Kwan 2000</a>), often requiring treatment with combinations of antiepileptic drugs. This presents a significant therapeutic problem when approximately 1% of the general population will suffer from epilepsy at some point in their lifetime (<a href="./references#CD001417-bbs2-0023" title="FiestKM , SauroKM , WiebeS , PattenSB , KwonCS , DykemanJ , et al. Prevalence and incidence of epilepsy: A systematic review and meta‐analysis of international studies. Neurology2017;88(3):296‐303. [PUBMED: 27986877] ">Fiest 2017</a>). </p> </section> <section id="CD001417-sec-0032"> <h3 class="title" id="CD001417-sec-0032">Description of the intervention</h3> <p>Over the past decade, there has been renewed interest in the development of newer antiepileptic drugs. This is largely because several of the standard antiepileptic drugs are not always successful at controlling seizures, and because some have been associated with certain adverse effects. In the first instance, new antiepileptic drugs are tested as an add‐on treatment for people with drug‐resistant focal epilepsy in randomised controlled trials (RCTs). Having demonstrated a therapeutic effect in these trials, new antiepileptic drugs tend to be licensed for add‐on use before monotherapy trials have been undertaken, in which new antiepileptic drugs are compared with standard ones. </p> </section> <section id="CD001417-sec-0033"> <h3 class="title" id="CD001417-sec-0033">How the intervention might work</h3> <p>There are an ever increasing number of licensed antiepileptic drugs from which to choose from, for people with drug‐resistant focal epilepsy. This review focuses upon the effects of topiramate, a drug whose mechanisms of action include a modulatory effect on voltage‐dependent sodium conductance (<a href="./references#CD001417-bbs2-0022" title="CoulterDA , SombatiS , DeLorenzoRJ . Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons. Epilepsia1993;34(Suppl 2):123. ">Coulter 1993</a>), enhancement of gamma‐aminobutyric acid‐A (GABAA)‐mediated chloride flux (<a href="./references#CD001417-bbs2-0020" title="BrownSD , WolfHH , SwinyardEA , TwymanRE , WhiteHS . The novel anticonvulsant topiramate enhances GABA‐mediated chloride flux. Epilepsia1993; Vol. 34, issue Suppl 2:122‐3. ">Brown 1993</a>), antagonism of kainate receptor‐mediated excitatory currents (<a href="./references#CD001417-bbs2-0025" title="GryderDS , RogawskiMA . Selective antagonism of GluR5 kainate‐receptor‐mediated synaptic currents by topiramate in rat basolateral amygdala neurons. The Journal of Neuroscience2003;23(18):7069‐74. [PUBMED: 12904467] ">Gryder 2003</a>), and inhibition of carbonic anhydrase, an enzyme necessary for GABAergic neurotransmission (<a href="./references#CD001417-bbs2-0026" title="HerreroAI , DelOlmoN , Gonzalez‐EscaladaJR , SolisJM . Two new actions of topiramate: inhibition of depolarizing GABA(A)‐mediated responses and activation of a potassium conductance. Neuropharmacology2002;42(2):210‐20. [PUBMED: 11804617] ">Herrero 2002</a>). Topiramate was licensed for add‐on use in the UK in 1996. </p> </section> <section id="CD001417-sec-0034"> <h3 class="title" id="CD001417-sec-0034">Why it is important to do this review</h3> <p>In this review, we summarise evidence from RCTs which have investigated the effects of topiramate in people with drug‐resistant focal epilepsy in order to aid clinical decision‐making when prescribing antiepileptic drug treatments within this population. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001417-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001417-sec-0035"></div> <p>To evaluate the efficacy and tolerability of topiramate when used as an add‐on treatment for people with drug‐resistant focal epilepsy. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001417-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001417-sec-0036"></div> <section id="CD001417-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001417-sec-0038"> <h4 class="title">Types of studies</h4> <p>Studies had to meet all of the following criteria.</p> <p> <ol id="CD001417-list-0001"> <li> <p>RCTs</p> </li> <li> <p>Double‐ or single‐blinded trials</p> </li> <li> <p>Placebo‐controlled</p> </li> <li> <p>Parallel‐group or cross‐over studies</p> </li> <li> <p>Minimum treatment period of eight weeks</p> </li> </ol> </p> </section> <section id="CD001417-sec-0039"> <h4 class="title">Types of participants</h4> <p>People of any age with drug‐resistant focal epilepsy (i.e. experiencing simple focal, complex focal or secondarily generalised tonic‐clonic seizures). </p> </section> <section id="CD001417-sec-0040"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD001417-list-0002"> <li> <p>The active treatment group received treatment with topiramate in addition to conventional antiepileptic drug treatment. </p> </li> <li> <p>The control group received a matched placebo or an alternative dose of topiramate in addition to conventional antiepileptic drug treatment. </p> </li> </ol> </p> </section> <section id="CD001417-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD001417-sec-0042"> <h5 class="title">Primary outcomes</h5> <section id="CD001417-sec-0043"> <h6 class="title">50% or greater reduction in seizure frequency</h6> <p>The primary outcome is the proportion of people with a 50% or greater reduction in seizure frequency in the treatment period compared to the pre‐randomisation baseline period. This outcome was chosen as it is commonly reported in this type of study. Furthermore, this outcome can also be calculated for studies which report baseline and follow‐up seizure frequencies. </p> </section> </section> <section id="CD001417-sec-0044"> <h5 class="title">Secondary outcomes</h5> <section id="CD001417-sec-0045"> <h6 class="title">Seizure freedom</h6> <p>The proportion of people with complete cessation of seizures during the treatment period. </p> </section> <section id="CD001417-sec-0046"> <h6 class="title">Treatment withdrawal</h6> <p>The proportion of people having treatment withdrawn during the course of the treatment period was used as a measure of 'global effectiveness'. Treatment is likely to be withdrawn due to adverse effects, lack of efficacy or a combination of both, and this is an outcome to which participants make a direct contribution. In trials of short duration, it is likely that adverse effects will be the most common reason for withdrawal. </p> </section> <section id="CD001417-sec-0047"> <h6 class="title">Adverse effects</h6> <p>The proportion of people experiencing:</p> <p> <ol id="CD001417-list-0003"> <li> <p>ataxia;</p> </li> <li> <p>dizziness;</p> </li> <li> <p>headache;</p> </li> <li> <p>nausea/vomiting;</p> </li> <li> <p>paraesthesias;</p> </li> <li> <p>weight loss/decrease;</p> </li> <li> <p>fatigue;</p> </li> <li> <p>somnolence;</p> </li> <li> <p>concentration impairment;</p> </li> <li> <p>speech difficulty;</p> </li> <li> <p>thinking abnormally.</p> </li> </ol> </p> <p>We chose these adverse effects as we considered them to be common and important adverse effects of antiepileptic drugs. </p> </section> </section> </section> </section> <section id="CD001417-sec-0048"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD001417-sec-0049"> <h4 class="title">Electronic searches</h4> <p>We ran searches for the original review on 18 June 2013, and subsequent searches in August 2016 and November 2016. For the latest update, we searched the following databases on 2 July 2018. </p> <p> <ol id="CD001417-list-0004"> <li> <p>Cochrane Register of Studies (CRS Web), which includes the Cochrane Epilepsy Group Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL), using the strategy outlined in <a href="./appendices#CD001417-sec-0100">Appendix 1</a>. </p> </li> <li> <p>MEDLINE (Ovid, 1946‐ ) using the strategy outlined in <a href="./appendices#CD001417-sec-0101">Appendix 2</a>. </p> </li> <li> <p><a href="https://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> using the strategy outlined in <a href="./appendices#CD001417-sec-0102">Appendix 3</a>. </p> </li> <li> <p><a href="http://apps.who.int/trialsearch/" target="_blank">WHO International Clinical Trials Registry Platform</a> (ICTRP) using the strategy outlined in <a href="./appendices#CD001417-sec-0103">Appendix 4</a>. </p> </li> </ol> </p> <p>There were no language restrictions.</p> <p>Previously we also searched SCOPUS (1823 to 18 June 2013) as an alternative to Embase, using the strategy outlined in <a href="./appendices#CD001417-sec-0104">Appendix 5</a>. This is no longer necessary, because randomised and quasi‐randomised controlled trials in Embase are now included in CENTRAL, so the SCOPUS search has not been updated. </p> </section> <section id="CD001417-sec-0050"> <h4 class="title">Searching other resources</h4> <p>We reviewed reference lists of included studies to search for additional reports of relevant studies and contacted Johnson and Johnson for information about any unpublished or ongoing studies. </p> </section> </section> <section id="CD001417-sec-0051"> <h3 class="title" id="CD001417-sec-0051">Data collection and analysis</h3> <section id="CD001417-sec-0052"> <h4 class="title">Selection of studies</h4> <p>For the update, two review authors (RB and JH) independently assessed trials for inclusion. Any disagreements were resolved by discussion with a third review author (AGM). Two review authors (RB and JH) extracted data and assessed risk of bias; disagreements again were resolved by discussion. </p> </section> <section id="CD001417-sec-0053"> <h4 class="title">Data extraction and management</h4> <p>We extracted the following information for each trial using a data extraction form.</p> <section id="CD001417-sec-0054"> <h5 class="title">Methodological/trial design</h5> <p> <ol id="CD001417-list-0005"> <li> <p>Method of randomisation and allocation concealment</p> </li> <li> <p>Method of blinding</p> </li> <li> <p>Whether any participants had been excluded from reported analyses</p> </li> <li> <p>Length of baseline period</p> </li> <li> <p>Length of treatment period</p> </li> <li> <p>Dose(s) of topiramate tested</p> </li> </ol> </p> </section> <section id="CD001417-sec-0055"> <h5 class="title">Patient/demographic information</h5> <p> <ol id="CD001417-list-0006"> <li> <p>Total number of participants allocated to each treatment group</p> </li> <li> <p>Age/sex</p> </li> <li> <p>Number with focal/generalised epilepsy</p> </li> <li> <p>Seizure types</p> </li> <li> <p>Seizure frequency during the baseline period</p> </li> <li> <p>Number of background drugs</p> </li> </ol> </p> <p>Most of the trials found were sponsored by Johnson and Johnson who were asked to confirm the following information. </p> <p> <ol id="CD001417-list-0007"> <li> <p>Method of randomisation</p> </li> <li> <p>Total number randomised to each group</p> </li> <li> <p>Number of participants in each group achieving a 50% or greater reduction in seizure frequency per treatment group </p> </li> <li> <p>Number of participants having treatment withdrawn post‐randomisation per treatment group </p> </li> <li> <p>For those excluded:</p> <ol id="CD001417-list-0008"> <li> <p>the reason for exclusion;</p> </li> <li> <p>whether any of those excluded completed the treatment phase;</p> </li> <li> <p>whether any of those excluded had a 50% or greater reduction in seizure frequency during the treatment phase. </p> </li> </ol> </li> </ol> </p> </section> <section id="CD001417-sec-0056"> <h5 class="title">Outcomes</h5> <p>We recorded the number of people experiencing each outcome (see <a href="#CD001417-sec-0041">Types of outcome measures</a>) per randomised group. We contacted authors of trials for any missing information. </p> </section> </section> <section id="CD001417-sec-0057"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (RB and JH) independently made an assessment of the risk of bias for each trial using the Cochrane 'Risk of bias' tool as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001417-bbs2-0027" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We discussed and resolved any disagreements. We rated the included studies as high risk, low risk or unclear risk for the six domains applicable to RCTs: randomisation method, allocation concealment, blinding methods, incomplete outcome data, selective outcome reporting and other sources of bias. </p> <p>We created 'Summary of findings' tables, and employed the GRADE approach for assessing certainty of evidence. </p> </section> <section id="CD001417-sec-0058"> <h4 class="title">Measures of treatment effect</h4> <p>We presented the primary outcome, 50% or greater reduction in seizure frequency, and the secondary outcomes, seizure freedom and treatment withdrawal, as risk ratios (RRs) with 95% confidence intervals (CIs). For the reporting of the individual adverse effects, we again presented the results as RRs, but instead quoted 99% CIs to compensate for multiple testing. By contrast, we reported the results from the dose regression model as odds ratios (ORs) with 95% CIs. </p> </section> <section id="CD001417-sec-0059"> <h4 class="title">Unit of analysis issues</h4> <p>There were no unit of analysis issues.</p> </section> <section id="CD001417-sec-0060"> <h4 class="title">Dealing with missing data</h4> <p>We sought any missing data from the study authors. We carried out intention‐to‐treat (ITT), best‐case and worst‐case analysis on the primary outcome to account for any missing data. All analyses are presented in the main report. </p> </section> <section id="CD001417-sec-0061"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical heterogeneity by comparing the distribution of important individual participant factors among trials (for example, age, seizure type, duration of epilepsy, number of antiepileptic drugs taken at the time of randomisation) and trial factors (for example, randomisation concealment, blinding, losses to follow‐up). We examined statistical heterogeneity using a Chi<sup>2</sup> test and the I<sup>2</sup> statistic for heterogeneity and, providing no heterogeneity was present (P &gt; 0.10), we employed a fixed‐effect model. In the event that heterogeneity was found, we planned to use a random‐effects model analysis using the inverse‐variance method. </p> </section> <section id="CD001417-sec-0062"> <h4 class="title">Assessment of reporting biases</h4> <p>We requested all protocols from study authors to enable a comparison of outcomes of interest. Outcome reporting bias was to be investigated using the ORBIT matrix system (<a href="./references#CD001417-bbs2-0028" title="KirkhamJJ , DwanKM , AltmanDG , GambleC , DoddS , SmythR , et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ2010;340:c365. [DOI: 10.1136/bmj.c365; PUBMED: 20156912] ">Kirkham 2010</a>). We also undertook visual examination of funnel plots as well as the Egger test, a statistical test to determine publication bias in meta‐analyses, to establish any publication bias. </p> </section> <section id="CD001417-sec-0063"> <h4 class="title">Data synthesis</h4> <p>We employed a fixed‐effect model meta‐analysis to synthesise the data for the comparison, topiramate versus placebo, for the outcomes: </p> <p> <ol id="CD001417-list-0009"> <li> <p>50% or greater reduction in seizure frequency;</p> </li> <li> <p>seizure freedom;</p> </li> <li> <p>treatment withdrawal;</p> </li> <li> <p>adverse effects.</p> </li> </ol> </p> <p>Each outcome was to be stratified by study characteristics to ensure the appropriate combination of study data. </p> <p>Our preferred estimator was the Mantel‐Haenszel RR. For the outcomes 50% or greater reduction in seizure frequency and treatment withdrawal, we used 95% CIs. For individual adverse effects we used 99% CIs to make an allowance for multiple testing. </p> <p>Our analyses included all participants in the treatment group to which they had been allocated. For the efficacy outcome, 50% or greater reduction in seizure frequency, we undertook three analyses, two of which were sensitivity analyses: </p> <p> <ol id="CD001417-list-0010"> <li> <p>Primary (ITT) analysis: participants from both treatment groups not completing follow‐up or with inadequate seizure data were assumed to be non‐responders. </p> <ol id="CD001417-list-0011"> <li> <p>Worst‐case analysis (sensitivity analysis): participants not completing follow‐up or with inadequate seizure data were assumed to be non‐responders in the intervention (topiramate) group, but were assumed to be responders in the placebo group. </p> </li> <li> <p>Best‐case analysis (sensitivity analysis): participants not completing follow‐up or with inadequate seizure data were assumed to be responders in the intervention (topiramate) group, but were assumed to be non‐responders in the placebo group. </p> </li> </ol> </li> </ol> </p> <p>The best‐case and worst‐case analyses served to determine whether the assumption made during ITT analysis (i.e. that all participants not completing follow‐up or with inadequate seizure data are non‐responders) grossly affected the estimated effect size. </p> <section id="CD001417-sec-0064"> <h5 class="title">Dose regression analysis</h5> <p>For the primary outcome, we examined the dose‐response relationship using a generalised linear mixed model with the xtmelogit in STATA SE version 14. The binary outcome was defined with the value '0' for patients who did not achieve a 50% or greater reduction in seizure frequency and was defined as the value '1' for patients who did. Study and dose were included as a fixed‐effect and a random‐effect was included for the treatment (no random‐effect for the constant term), as described in <a href="./references#CD001417-bbs2-0038" title="TurnerRM , OmarRZ , YangM , GoldsteinH , ThompsonSG . A multilevel model framework for meta‐analysis of clinical trials with binary outcomes. Statistics in Medicine2000;19(24):3417‐32. [PUBMED: 11122505] ">Turner 2000</a>. Dose was standardised by its standard deviation (351.9 mg/d). This method estimated an OR as opposed to a RR. We then used the command, meqrlogit, to predict the probabilities for the following: (i) the percentage of patients having a 50% response at differing doses; (ii) the difference in the percentage of patients responding to each dose compared to placebo. </p> </section> </section> <section id="CD001417-sec-0065"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We undertook subgroup analysis for adverse effects. We intended to investigate heterogeneity using sensitivity analysis if deemed appropriate. </p> </section> <section id="CD001417-sec-0066"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted five forms of sensitivity analyses in total during the data synthesis. Two such sensitivity analyses were highlighted and explained earlier, best‐ and worst‐case analysis (see <a href="#CD001417-sec-0063">Data synthesis</a>). We also intended to carry out sensitivity analysis if peculiarities were found between study quality, characteristics of participants, interventions and outcomes. Specifically, we detected heterogeneity in the outcome, 50% or greater reduction in seizure frequency, and, therefore, we applied the following sensitivity analysis according to: study quality (we excluded studies with either high or unclear risk of bias) and age (we excluded one study because it included paediatric participants). Finally, we conducted a sensitivity according to dosage. We excluded three studies because all three only assessed dose of 200 mg/d topiramate. </p> <section id="CD001417-sec-0067"> <h5 class="title">Summarising and interpreting results using GRADE</h5> <p>We used the GRADE approach, as outlined in the GRADE Handbook (<a href="./references#CD001417-bbs2-0037" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s) . Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html. ">Schünemann 2013</a>), to assess the certainty of evidence and to interpret findings. We used GRADEpro GDT software (<a href="./references#CD001417-bbs2-0024" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 17 January 2019. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT 2015</a>), which imports data from Review Manager 5 software (<a href="./references#CD001417-bbs2-0034" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>), to create a 'Summary of findings' table for the following outcomes: 50% or greater reduction in seizure frequency, seizure freedom, treatment withdrawal, weight loss/decrease, paraesthesia, thinking abnormally, and difficulty with concentration. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001417-sec-0068" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001417-sec-0068"></div> <section id="CD001417-sec-0069"> <h3 class="title">Description of studies</h3> <section id="CD001417-sec-0070"> <h4 class="title">Results of the search</h4> <p>The search revealed 1346 records identified from the databases, outlined in <a href="#CD001417-sec-0049">Electronic searches</a>. After removing 541 duplicates, 805 records remained and we screened all for inclusion in the review. We excluded 758 records at this point due to irrelevance, leaving 46 records to be assessed for eligibility at the full‐text stage of screening. Following this, we excluded five studies, linked to seven individual records (see <a href="#CD001417-fig-0001">Figure 1</a> and <a href="./references#CD001417-sec-0115" title="">Characteristics of excluded studies</a> for reasons of exclusion). We included a total of 12 studies (linked to 37 individual records) in the review, all of which we included in meta‐analyses. We identified two abstracts (two records) as studies awaiting classification and contacted the authors of these studies for more information. At the time of publication, no correspondence had been received. </p> <div class="figure" id="CD001417-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD001417-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD001417-sec-0071"> <h4 class="title">Included studies</h4> <p>The 12 RCTs identified by the screening process recruited a total of 1650 participants and between them tested doses of 200 mg, 300 mg, 400 mg, 600 mg, 800 mg and 1000 mg topiramate per day. For further information on each trial, see <a href="./references#CD001417-sec-0114" title="">Characteristics of included studies</a>. </p> <p>Overall, there were 10 randomised controlled trials (RCTs) which compared topiramate to placebo in adults aged 18 to 75 years (<a href="./references#CD001417-bbs2-0001" title="Ben‐MenachemE , DamM , HenriksenO , SchmidtD . Double‐blind, placebo‐controlled trial of 800 mg/day topiramate as add‐on therapy in patients with refractory partial epilepsy. Epilepsia1995;36(Suppl 3):S150. Ben‐MenachemE , DamM , MikkelsenM , EngelskjonT , HenriksenO , JohannessenS , et al. Topiramate add‐on treatment in patients with intractable partial epilepsy: a multicenter study. Epilepsia1993;34(Suppl 2):109. Ben‐MenachemE , HenriksenO , DamM , MikkelsenM , SchmidtD , ReidS , et al. Double‐blind, placebo‐controlled trial of topiramate as add‐on therapy in patients with refractory partial seizures. Epilepsia1996;37(6):539‐43. [PUBMED: 8641230] Martinez‐LageJ , Ben‐MenachemE , ShorvonSD , WeberM . Double‐blind, placebo‐controlled trial of 400 mg/day topiramate as add‐on therapy in patients with refractory partial epilepsy. Epilepsia1995;36(Suppl 3):S149‐50. OstergardL , DamM , MikkelsenM . Topiramate as add‐on therapy in refractory partial epilepsy. Epilepsia1992;33(Suppl 3):105. ">Ben‐Menachem 1996</a>; <a href="./references#CD001417-bbs2-0002" title="ArnoldS , BlattI , ClarkAM , HalvorsenMB , NagaraddiVN . USL255, a once‐daily, extended‐release topiramate, has positive effects on clinical outcomes and quality of life: results from the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):105, Abstract no: 1.223. BlattI , ChungSS , HoganRE , ClarkA , AndersB , HalvorsenM . Efficacy and safety of USL255, once‐daily extended‐release topiramate, in adults with partial onset seizures: the PREVAIL study. Epilepsia2014;55(Suppl 2):42‐43, Abstract no: p112. BlattI , NagaraddiV , HoganR , ArnoldS , LawsonB , AndersB , et al. Efficacy of USL255 across partial‐onset seizure types and refractory patient status: subgroup analyses from the PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.263. BlattI , NagaraddiVN , AndersB , ClarkAM , HalvorsenMB , HoganRE . USL255 is efficacious across all partial‐onset seizure types and with a variety of concomitant antiepileptic drugs: Results from subgroup analyses of the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):204, Abstract no: 2.116. ChungS . USL255 extended‐release topiramate for the treatment of epilepsy. Expert Review of Neurotherapeutics2014;14(10):1127‐37. [PUBMED: 25220748] ChungSS . A review of the efficacy and safety of extended‐release topiramate in the adjunctive treatment for refractory partial‐onset seizures. Therapeutic Advances in Neurological Disorders2015;8(3):131‐6. [PUBMED: 25941540] ChungSS , FakhouryTA , HoganRE , NagaraddiVN , BlattI , LawsonB , et al. Once‐daily USL255 as adjunctive treatment of partial‐onset seizures: randomized phase III study. Epilepsia2014;55(7):1077‐87. [PUBMED: 24902983] ChungSS , HoganR , BlattI , LawsonPB , NguyenH , ClarkAM , et al. Long‐term safety and sustained efficacy of USL255 (topiramate extended‐release capsules) in patients with refractory partial‐onset seizures. Epilepsy &amp; Behavior2016;59:13‐20. [PUBMED: 27084978] ClarkAM , ChungSS , BlattI , AndersB , HalvorsenMB , HoganRE . Efficacy of USL255 (qudexyTM XR; Extended‐release topiramate) in patients with refractory partial‐onset seizures: PREVAIL and PREVAIL OLE. Epilepsy Currents2015;15(Suppl 1):142‐3, Abstract no: 1.307. HoganR , ArnoldS , FakhouryT , AndersB . Adverse event profile of USL255 in patients with refractory partial‐onset seizures: the PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.262. HoganRE , ArnoldS , FakhouryTA , AndersB , LaineD , ToddWM , et al. Safety and tolerability of USL255 in subjects with refractory partial‐onset seizures: results from the randomized, phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):103‐4, Abstract no: 1.219. HoganRE , BlattI , LawsonB , NagaraddiV , FakhouryTA , AndersB , et al. Efficacy of once‐daily extended‐release topiramate (USL255): a subgroup analysis based on the level of treatment resistance. Epilepsy &amp; Behavior2014;41:136‐9. [PUBMED: 25461205] LawsonB , ChungSS , ClarkAM , HalvorsenMB , BlattI . Time to onset of efficacy and sustained treatment effects of USL255: results from the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):104, Abstract no: 1.222. NagaraddiV , ChungS , ArnoldS , ClarkA , AndersB , FakhouryT . Early onset of efficacy and safety outcomes with USL255 treatment: The PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.264. ">Chung 2014</a>; <a href="./references#CD001417-bbs2-0004" title="FaughtE , WilderBJ , RamsayRE . Topiramate dose‐ranging trial in refractory partial epilepsy. Epilepsia1995;36(Suppl 4):33, Abstract no: D.9. FaughtE , WilderBJ , RamsayRE , ReifeRA , KramerLD , PledgerGW , et al. Topiramate placebo‐controlled dose‐ranging trial in refractory partial epilepsy using 200‐, 400‐, and 600‐mg daily dosages. Neurology1996;46(6):1684‐90. [PUBMED: 8649570] ">Faught 1996</a>; <a href="./references#CD001417-bbs2-0005" title="GubermanA , NetoW , Gassmann‐MayerC , EPAJ‐119 Study Group. Low‐dose topiramate in adults with treatment‐resistant partial‐onset seizures. Acta Neurologica Scandinavica2002;106(4):183‐9. [PUBMED: 12225311] GubermanA , NetoW , Gassmann‐MayerC , Topiramate EPAJ‐119 Study Group. Efficacy of 200 mg/day topiramate in treatment‐resistant partial seizures when added to an enzyme‐inducing anti‐epileptic drug (AED). Epilepsia2001;42(Suppl 7):179‐80, Abstract no: 2.244. NetoW , Gassmann‐MayerC , Topiramate EPAJ‐119 study group. Efficacy and tolerability of 200 mg/day topiramate in a placebo‐controlled comparison of titration rates. Epilepsia2000;41:35. VanOeneJ , NetoW , NilssonJ , HamiltonG , BaetenB , SchreinerA , et al. Weight reduction during topiramate treatment of partial seizures. Epilepsia2002;43(Suppl 8):152, Abstract no: P482. ">Guberman 2002</a>; <a href="./references#CD001417-bbs2-0006" title="Korean Topiramate Study Group. Topiramate in medically intractable partial epilepsies: double‐blind placebo‐controlled randomized parallel group trial. Epilepsia1999;40(12):1767‐74. [PUBMED: 10612342] LeeBI . Double‐blind placebo‐controlled randomized clinical trial of topiramate add‐on therapy in medically intractable partial epilepsies. Journal of the Korean Neurology Association1998;16(6):809‐19. ">Korean Topiramate Study Group 1999</a>; <a href="./references#CD001417-bbs2-0007" title="PriviteraM , FinchamR , PenryJ , ReifeR , KramerL , PledgerG , et al. Topiramate placebo‐controlled dose‐ranging trial in refractory partial epilepsy using 600‐, 800‐, and 1,000‐mg daily dosages. Neurology1996;46(6):1678‐83. [PUBMED: 8649569] PriviteraM , FinchamR , PenryJK . Dose‐ranging trial with higher doses of topiramate in patients with resistant partial seizures. Epilepsia1995;36(Suppl 4):33, Abstract no: D.7. ">Privitera 1996</a>; <a href="./references#CD001417-bbs2-0008" title="RosenfeldW , Abou‐KhalilB , ReifeR , HegadusR , PledgerG , Topiramate YF/YG Study Group. Placebo‐controlled trial of topiramate as adjunctive therapy to carbamazepine or phenytoin for partial‐onset seizures. Epilepsia1996;37(Suppl 5):153, Abstract no: 6.7. ">Rosenfeld 1996;</a><a href="./references#CD001417-bbs2-0009" title="ShariefM , ViteriC , Ben‐MenachemE , WeberM , ReifeR , PledgerG , et al. Double‐blind, placebo‐controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Research1996;25(3):217‐24. [PUBMED: 8956919] ShariefMK , SanderJW , PatsalosPN , ShorvonSD . Adjuvant topiramate treatment in intractable partial epilepsy. Epilepsia1993;6:41. ">Sharief 1996</a>; <a href="./references#CD001417-bbs2-0010" title="TassinariC , ChauvelP , ChodkiewiczJ , ShorvonSD , HenriksenO , DamM , et al. Double‐blind, placebo‐controlled trial of 600 mg/day topiramate as add‐on therapy in patients with refractory partial epilepsy. Epilepsia1995;36(Suppl 3):S150. TassinariCA , MichelucciR , ChauvelP , ChodkiewiczJ , ShorvonS , HenriksenO , et al. Double‐blind, placebo‐controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia1996;37(8):763‐8. [PUBMED: 8764816] ">Tassinari 1996</a>; <a href="./references#CD001417-bbs2-0011" title="YenDJ , YuHY , GuoYC , ChenC , YiuCH , SuMS . A double‐blind, placebo‐controlled study of topiramate in adult patients with refractory partial epilepsy. Epilepsia2000;41(9):1162‐6. [PUBMED: 10999555] ">Yen 2000</a>), one RCT which examined topiramate versus a placebo in children (<a href="./references#CD001417-bbs2-0003" title="EltermanRD , GlauserTA , WyllieE , ReifeR , WuSC , PledgerG , et al. A double‐blind, randomized trial of topiramate as adjunctive therapy for partial‐onset seizures in children. Neurology1999;52(7):1338‐44. [PUBMED: 10227615] ">Elterman 1999</a>), and one other RCT which examined the same comparison within the elderly (<a href="./references#CD001417-bbs2-0012" title="ZhangL , HuangJ , ZhuangJH , HuangLQ , ZhaoZX . Topiramate as an adjunctive treatment for refractory partial epilepsy in the elderly. Journal of International Medical Research2011;39(2):408‐15. [PUBMED: 21672344] ">Zhang 2011</a>). Eight of these trials were sponsored by Johnson and Johnson. In all of the trials, participants were eligible to take part in the double‐blind part of the trials if they were found to experience a minimum number of focal seizures (range 3 to 12 seizures) and were currently taking one to two or one to three antiepileptic drug treatments. See <a href="#CD001417-tbl-0002">Table 1</a> for comparison of study characteristics. </p> <div class="table" id="CD001417-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study characteristics</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study name</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of previous AEDs</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline period</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment period</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001417-bbs2-0001" title="Ben‐MenachemE , DamM , HenriksenO , SchmidtD . Double‐blind, placebo‐controlled trial of 800 mg/day topiramate as add‐on therapy in patients with refractory partial epilepsy. Epilepsia1995;36(Suppl 3):S150. Ben‐MenachemE , DamM , MikkelsenM , EngelskjonT , HenriksenO , JohannessenS , et al. Topiramate add‐on treatment in patients with intractable partial epilepsy: a multicenter study. Epilepsia1993;34(Suppl 2):109. Ben‐MenachemE , HenriksenO , DamM , MikkelsenM , SchmidtD , ReidS , et al. Double‐blind, placebo‐controlled trial of topiramate as add‐on therapy in patients with refractory partial seizures. Epilepsia1996;37(6):539‐43. [PUBMED: 8641230] Martinez‐LageJ , Ben‐MenachemE , ShorvonSD , WeberM . Double‐blind, placebo‐controlled trial of 400 mg/day topiramate as add‐on therapy in patients with refractory partial epilepsy. Epilepsia1995;36(Suppl 3):S149‐50. OstergardL , DamM , MikkelsenM . Topiramate as add‐on therapy in refractory partial epilepsy. Epilepsia1992;33(Suppl 3):105. ">Ben‐Menachem 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sweden, Norway, Denmark, Germany</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001417-bbs2-0002" title="ArnoldS , BlattI , ClarkAM , HalvorsenMB , NagaraddiVN . USL255, a once‐daily, extended‐release topiramate, has positive effects on clinical outcomes and quality of life: results from the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):105, Abstract no: 1.223. BlattI , ChungSS , HoganRE , ClarkA , AndersB , HalvorsenM . Efficacy and safety of USL255, once‐daily extended‐release topiramate, in adults with partial onset seizures: the PREVAIL study. Epilepsia2014;55(Suppl 2):42‐43, Abstract no: p112. BlattI , NagaraddiV , HoganR , ArnoldS , LawsonB , AndersB , et al. Efficacy of USL255 across partial‐onset seizure types and refractory patient status: subgroup analyses from the PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.263. BlattI , NagaraddiVN , AndersB , ClarkAM , HalvorsenMB , HoganRE . USL255 is efficacious across all partial‐onset seizure types and with a variety of concomitant antiepileptic drugs: Results from subgroup analyses of the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):204, Abstract no: 2.116. ChungS . USL255 extended‐release topiramate for the treatment of epilepsy. Expert Review of Neurotherapeutics2014;14(10):1127‐37. [PUBMED: 25220748] ChungSS . A review of the efficacy and safety of extended‐release topiramate in the adjunctive treatment for refractory partial‐onset seizures. Therapeutic Advances in Neurological Disorders2015;8(3):131‐6. [PUBMED: 25941540] ChungSS , FakhouryTA , HoganRE , NagaraddiVN , BlattI , LawsonB , et al. Once‐daily USL255 as adjunctive treatment of partial‐onset seizures: randomized phase III study. Epilepsia2014;55(7):1077‐87. [PUBMED: 24902983] ChungSS , HoganR , BlattI , LawsonPB , NguyenH , ClarkAM , et al. Long‐term safety and sustained efficacy of USL255 (topiramate extended‐release capsules) in patients with refractory partial‐onset seizures. Epilepsy &amp; Behavior2016;59:13‐20. [PUBMED: 27084978] ClarkAM , ChungSS , BlattI , AndersB , HalvorsenMB , HoganRE . Efficacy of USL255 (qudexyTM XR; Extended‐release topiramate) in patients with refractory partial‐onset seizures: PREVAIL and PREVAIL OLE. Epilepsy Currents2015;15(Suppl 1):142‐3, Abstract no: 1.307. HoganR , ArnoldS , FakhouryT , AndersB . Adverse event profile of USL255 in patients with refractory partial‐onset seizures: the PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.262. HoganRE , ArnoldS , FakhouryTA , AndersB , LaineD , ToddWM , et al. Safety and tolerability of USL255 in subjects with refractory partial‐onset seizures: results from the randomized, phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):103‐4, Abstract no: 1.219. HoganRE , BlattI , LawsonB , NagaraddiV , FakhouryTA , AndersB , et al. Efficacy of once‐daily extended‐release topiramate (USL255): a subgroup analysis based on the level of treatment resistance. Epilepsy &amp; Behavior2014;41:136‐9. [PUBMED: 25461205] LawsonB , ChungSS , ClarkAM , HalvorsenMB , BlattI . Time to onset of efficacy and sustained treatment effects of USL255: results from the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):104, Abstract no: 1.222. NagaraddiV , ChungS , ArnoldS , ClarkA , AndersB , FakhouryT . Early onset of efficacy and safety outcomes with USL255 treatment: The PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.264. ">Chung 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Argentina, Australia, Belgium, Canada, Chile, Germany, Greece, Hungary, India, Israel, New Zealand, Poland, Russia, South Africa, Spain, USA </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 to ≥7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001417-bbs2-0003" title="EltermanRD , GlauserTA , WyllieE , ReifeR , WuSC , PledgerG , et al. A double‐blind, randomized trial of topiramate as adjunctive therapy for partial‐onset seizures in children. Neurology1999;52(7):1338‐44. [PUBMED: 10227615] ">Elterman 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA, Costa Rica</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001417-bbs2-0004" title="FaughtE , WilderBJ , RamsayRE . Topiramate dose‐ranging trial in refractory partial epilepsy. Epilepsia1995;36(Suppl 4):33, Abstract no: D.9. FaughtE , WilderBJ , RamsayRE , ReifeRA , KramerLD , PledgerGW , et al. Topiramate placebo‐controlled dose‐ranging trial in refractory partial epilepsy using 200‐, 400‐, and 600‐mg daily dosages. Neurology1996;46(6):1684‐90. [PUBMED: 8649570] ">Faught 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>181</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001417-bbs2-0005" title="GubermanA , NetoW , Gassmann‐MayerC , EPAJ‐119 Study Group. Low‐dose topiramate in adults with treatment‐resistant partial‐onset seizures. Acta Neurologica Scandinavica2002;106(4):183‐9. [PUBMED: 12225311] GubermanA , NetoW , Gassmann‐MayerC , Topiramate EPAJ‐119 Study Group. Efficacy of 200 mg/day topiramate in treatment‐resistant partial seizures when added to an enzyme‐inducing anti‐epileptic drug (AED). Epilepsia2001;42(Suppl 7):179‐80, Abstract no: 2.244. NetoW , Gassmann‐MayerC , Topiramate EPAJ‐119 study group. Efficacy and tolerability of 200 mg/day topiramate in a placebo‐controlled comparison of titration rates. Epilepsia2000;41:35. VanOeneJ , NetoW , NilssonJ , HamiltonG , BaetenB , SchreinerA , et al. Weight reduction during topiramate treatment of partial seizures. Epilepsia2002;43(Suppl 8):152, Abstract no: P482. ">Guberman 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hungary, Poland, Israel, Canada, Russia, Czech Republic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>263</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001417-bbs2-0006" title="Korean Topiramate Study Group. Topiramate in medically intractable partial epilepsies: double‐blind placebo‐controlled randomized parallel group trial. Epilepsia1999;40(12):1767‐74. [PUBMED: 10612342] LeeBI . Double‐blind placebo‐controlled randomized clinical trial of topiramate add‐on therapy in medically intractable partial epilepsies. Journal of the Korean Neurology Association1998;16(6):809‐19. ">Korean Topiramate Study Group 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Korea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>177</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001417-bbs2-0007" title="PriviteraM , FinchamR , PenryJ , ReifeR , KramerL , PledgerG , et al. Topiramate placebo‐controlled dose‐ranging trial in refractory partial epilepsy using 600‐, 800‐, and 1,000‐mg daily dosages. Neurology1996;46(6):1678‐83. [PUBMED: 8649569] PriviteraM , FinchamR , PenryJK . Dose‐ranging trial with higher doses of topiramate in patients with resistant partial seizures. Epilepsia1995;36(Suppl 4):33, Abstract no: D.7. ">Privitera 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>190</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001417-bbs2-0008" title="RosenfeldW , Abou‐KhalilB , ReifeR , HegadusR , PledgerG , Topiramate YF/YG Study Group. Placebo‐controlled trial of topiramate as adjunctive therapy to carbamazepine or phenytoin for partial‐onset seizures. Epilepsia1996;37(Suppl 5):153, Abstract no: 6.7. ">Rosenfeld 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>209</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001417-bbs2-0009" title="ShariefM , ViteriC , Ben‐MenachemE , WeberM , ReifeR , PledgerG , et al. Double‐blind, placebo‐controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Research1996;25(3):217‐24. [PUBMED: 8956919] ShariefMK , SanderJW , PatsalosPN , ShorvonSD . Adjuvant topiramate treatment in intractable partial epilepsy. Epilepsia1993;6:41. ">Sharief 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sweden, Spain, UK, France</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001417-bbs2-0010" title="TassinariC , ChauvelP , ChodkiewiczJ , ShorvonSD , HenriksenO , DamM , et al. Double‐blind, placebo‐controlled trial of 600 mg/day topiramate as add‐on therapy in patients with refractory partial epilepsy. Epilepsia1995;36(Suppl 3):S150. TassinariCA , MichelucciR , ChauvelP , ChodkiewiczJ , ShorvonS , HenriksenO , et al. Double‐blind, placebo‐controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia1996;37(8):763‐8. [PUBMED: 8764816] ">Tassinari 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK, Italy, France, Norway, Denmark</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001417-bbs2-0011" title="YenDJ , YuHY , GuoYC , ChenC , YiuCH , SuMS . A double‐blind, placebo‐controlled study of topiramate in adult patients with refractory partial epilepsy. Epilepsia2000;41(9):1162‐6. [PUBMED: 10999555] ">Yen 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001417-bbs2-0012" title="ZhangL , HuangJ , ZhuangJH , HuangLQ , ZhaoZX . Topiramate as an adjunctive treatment for refractory partial epilepsy in the elderly. Journal of International Medical Research2011;39(2):408‐15. [PUBMED: 21672344] ">Zhang 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Elderly</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AED: antiepileptic drug</p> </div> </div> <p>One multicentre, parallel trial had a pre‐randomisation period of eight weeks and a treatment period of 13 weeks (<a href="./references#CD001417-bbs2-0001" title="Ben‐MenachemE , DamM , HenriksenO , SchmidtD . Double‐blind, placebo‐controlled trial of 800 mg/day topiramate as add‐on therapy in patients with refractory partial epilepsy. Epilepsia1995;36(Suppl 3):S150. Ben‐MenachemE , DamM , MikkelsenM , EngelskjonT , HenriksenO , JohannessenS , et al. Topiramate add‐on treatment in patients with intractable partial epilepsy: a multicenter study. Epilepsia1993;34(Suppl 2):109. Ben‐MenachemE , HenriksenO , DamM , MikkelsenM , SchmidtD , ReidS , et al. Double‐blind, placebo‐controlled trial of topiramate as add‐on therapy in patients with refractory partial seizures. Epilepsia1996;37(6):539‐43. [PUBMED: 8641230] Martinez‐LageJ , Ben‐MenachemE , ShorvonSD , WeberM . Double‐blind, placebo‐controlled trial of 400 mg/day topiramate as add‐on therapy in patients with refractory partial epilepsy. Epilepsia1995;36(Suppl 3):S149‐50. OstergardL , DamM , MikkelsenM . Topiramate as add‐on therapy in refractory partial epilepsy. Epilepsia1992;33(Suppl 3):105. ">Ben‐Menachem 1996</a>), randomising 56 adults to one of two treatment arms: 800 mg of topiramate (n = 28) or placebo (n = 28). The study medication was administered twice daily or to the maximal tolerated dose. </p> <p>Similarly, a multicentre, parallel trial had a pre‐randomisation baseline period of eight weeks (<a href="./references#CD001417-bbs2-0002" title="ArnoldS , BlattI , ClarkAM , HalvorsenMB , NagaraddiVN . USL255, a once‐daily, extended‐release topiramate, has positive effects on clinical outcomes and quality of life: results from the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):105, Abstract no: 1.223. BlattI , ChungSS , HoganRE , ClarkA , AndersB , HalvorsenM . Efficacy and safety of USL255, once‐daily extended‐release topiramate, in adults with partial onset seizures: the PREVAIL study. Epilepsia2014;55(Suppl 2):42‐43, Abstract no: p112. BlattI , NagaraddiV , HoganR , ArnoldS , LawsonB , AndersB , et al. Efficacy of USL255 across partial‐onset seizure types and refractory patient status: subgroup analyses from the PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.263. BlattI , NagaraddiVN , AndersB , ClarkAM , HalvorsenMB , HoganRE . USL255 is efficacious across all partial‐onset seizure types and with a variety of concomitant antiepileptic drugs: Results from subgroup analyses of the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):204, Abstract no: 2.116. ChungS . USL255 extended‐release topiramate for the treatment of epilepsy. Expert Review of Neurotherapeutics2014;14(10):1127‐37. [PUBMED: 25220748] ChungSS . A review of the efficacy and safety of extended‐release topiramate in the adjunctive treatment for refractory partial‐onset seizures. Therapeutic Advances in Neurological Disorders2015;8(3):131‐6. [PUBMED: 25941540] ChungSS , FakhouryTA , HoganRE , NagaraddiVN , BlattI , LawsonB , et al. Once‐daily USL255 as adjunctive treatment of partial‐onset seizures: randomized phase III study. Epilepsia2014;55(7):1077‐87. [PUBMED: 24902983] ChungSS , HoganR , BlattI , LawsonPB , NguyenH , ClarkAM , et al. Long‐term safety and sustained efficacy of USL255 (topiramate extended‐release capsules) in patients with refractory partial‐onset seizures. Epilepsy &amp; Behavior2016;59:13‐20. [PUBMED: 27084978] ClarkAM , ChungSS , BlattI , AndersB , HalvorsenMB , HoganRE . Efficacy of USL255 (qudexyTM XR; Extended‐release topiramate) in patients with refractory partial‐onset seizures: PREVAIL and PREVAIL OLE. Epilepsy Currents2015;15(Suppl 1):142‐3, Abstract no: 1.307. HoganR , ArnoldS , FakhouryT , AndersB . Adverse event profile of USL255 in patients with refractory partial‐onset seizures: the PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.262. HoganRE , ArnoldS , FakhouryTA , AndersB , LaineD , ToddWM , et al. Safety and tolerability of USL255 in subjects with refractory partial‐onset seizures: results from the randomized, phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):103‐4, Abstract no: 1.219. HoganRE , BlattI , LawsonB , NagaraddiV , FakhouryTA , AndersB , et al. Efficacy of once‐daily extended‐release topiramate (USL255): a subgroup analysis based on the level of treatment resistance. Epilepsy &amp; Behavior2014;41:136‐9. [PUBMED: 25461205] LawsonB , ChungSS , ClarkAM , HalvorsenMB , BlattI . Time to onset of efficacy and sustained treatment effects of USL255: results from the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):104, Abstract no: 1.222. NagaraddiV , ChungS , ArnoldS , ClarkA , AndersB , FakhouryT . Early onset of efficacy and safety outcomes with USL255 treatment: The PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.264. ">Chung 2014</a>). This trial featured a shorter treatment period of 11 weeks and consisted of two treatment arms. Two hundred and forty‐nine participants were randomised to either placebo (n = 125) or 200 mg/d topiramate (n = 124). </p> <p>The <a href="./references#CD001417-bbs2-0003" title="EltermanRD , GlauserTA , WyllieE , ReifeR , WuSC , PledgerG , et al. A double‐blind, randomized trial of topiramate as adjunctive therapy for partial‐onset seizures in children. Neurology1999;52(7):1338‐44. [PUBMED: 10227615] ">Elterman 1999</a> multicentre (USA, Costa Rica), parallel trial, randomised 41 children aged one to 16 years to topiramate and 45 to placebo. Participants were eligible if they experienced six or more seizures during baseline and were taking one or two antiepileptic drugs. The baseline period was eight weeks in duration with a treatment period of 16 weeks. </p> <p>Another parallel trial from the USA had three different treatment arms and a placebo arm (<a href="./references#CD001417-bbs2-0004" title="FaughtE , WilderBJ , RamsayRE . Topiramate dose‐ranging trial in refractory partial epilepsy. Epilepsia1995;36(Suppl 4):33, Abstract no: D.9. FaughtE , WilderBJ , RamsayRE , ReifeRA , KramerLD , PledgerGW , et al. Topiramate placebo‐controlled dose‐ranging trial in refractory partial epilepsy using 200‐, 400‐, and 600‐mg daily dosages. Neurology1996;46(6):1684‐90. [PUBMED: 8649570] ">Faught 1996</a>). Forty‐five adults aged 18 to 65 years were randomised to 200 mg per day of topiramate, 45 mg to 400 mg per day topiramate or 46 mg to 600 mg per day topiramate and 45 were randomised to the placebo group. This trial had a baseline period of 12 weeks and a treatment period of 16 weeks. </p> <p>A further multicentre, parallel trial (<a href="./references#CD001417-bbs2-0005" title="GubermanA , NetoW , Gassmann‐MayerC , EPAJ‐119 Study Group. Low‐dose topiramate in adults with treatment‐resistant partial‐onset seizures. Acta Neurologica Scandinavica2002;106(4):183‐9. [PUBMED: 12225311] GubermanA , NetoW , Gassmann‐MayerC , Topiramate EPAJ‐119 Study Group. Efficacy of 200 mg/day topiramate in treatment‐resistant partial seizures when added to an enzyme‐inducing anti‐epileptic drug (AED). Epilepsia2001;42(Suppl 7):179‐80, Abstract no: 2.244. NetoW , Gassmann‐MayerC , Topiramate EPAJ‐119 study group. Efficacy and tolerability of 200 mg/day topiramate in a placebo‐controlled comparison of titration rates. Epilepsia2000;41:35. VanOeneJ , NetoW , NilssonJ , HamiltonG , BaetenB , SchreinerA , et al. Weight reduction during topiramate treatment of partial seizures. Epilepsia2002;43(Suppl 8):152, Abstract no: P482. ">Guberman 2002</a>), randomised adults to one of three treatment arms: topiramate escalated weekly by 25 mg to 200 mg per day (n = 85), topiramate escalated weekly by 50 mg to 200 mg per day (n = 83), and placebo (n = 91). This trial had a baseline period of four weeks and a titration period of eight weeks for the 25 mg group or four weeks for the 50 mg group. The double‐blind treatment phase was 12 weeks in duration. </p> <p>The parallel trial run by the Korean Topiramate Study Group (<a href="./references#CD001417-bbs2-0006" title="Korean Topiramate Study Group. Topiramate in medically intractable partial epilepsies: double‐blind placebo‐controlled randomized parallel group trial. Epilepsia1999;40(12):1767‐74. [PUBMED: 10612342] LeeBI . Double‐blind placebo‐controlled randomized clinical trial of topiramate add‐on therapy in medically intractable partial epilepsies. Journal of the Korean Neurology Association1998;16(6):809‐19. ">Korean Topiramate Study Group 1999</a>), investigated adults only and consisted of two main treatment arms including 600 mg topiramate (n = 91) and placebo (n = 86). The baseline period was 12 weeks in duration followed by a titration period of 10 weeks and then a stabilisation period of eight weeks. </p> <p>A multicentre, parallel trial had a 12‐week baseline period followed by an 18‐week double‐blind treatment period (<a href="./references#CD001417-bbs2-0007" title="PriviteraM , FinchamR , PenryJ , ReifeR , KramerL , PledgerG , et al. Topiramate placebo‐controlled dose‐ranging trial in refractory partial epilepsy using 600‐, 800‐, and 1,000‐mg daily dosages. Neurology1996;46(6):1678‐83. [PUBMED: 8649569] PriviteraM , FinchamR , PenryJK . Dose‐ranging trial with higher doses of topiramate in patients with resistant partial seizures. Epilepsia1995;36(Suppl 4):33, Abstract no: D.7. ">Privitera 1996</a>). Within this phase was a six‐week titration period and 12‐week stabilisation period. Adults were randomised to one of four treatment arms: 48 mg to 600 mg per day topiramate, 48 mg to 800 mg per day topiramate, 47 mg to 1000 mg per day topiramate and 47 were randomised to placebo. </p> <p>Another multicentre, parallel trial had an eight‐week baseline period and a 19‐week treatment period (<a href="./references#CD001417-bbs2-0008" title="RosenfeldW , Abou‐KhalilB , ReifeR , HegadusR , PledgerG , Topiramate YF/YG Study Group. Placebo‐controlled trial of topiramate as adjunctive therapy to carbamazepine or phenytoin for partial‐onset seizures. Epilepsia1996;37(Suppl 5):153, Abstract no: 6.7. ">Rosenfeld 1996</a>). Two hundred and nine adults were randomised to one of two treatment arms in a ratio of 1:3, resulting in 42 patients being randomised to placebo and 167 patients being randomised to 1000 mg per day topiramate. </p> <p>Another multicentre, parallel trial had a pre‐randomisation period of eight weeks and a treatment period of 11 weeks (<a href="./references#CD001417-bbs2-0009" title="ShariefM , ViteriC , Ben‐MenachemE , WeberM , ReifeR , PledgerG , et al. Double‐blind, placebo‐controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Research1996;25(3):217‐24. [PUBMED: 8956919] ShariefMK , SanderJW , PatsalosPN , ShorvonSD . Adjuvant topiramate treatment in intractable partial epilepsy. Epilepsia1993;6:41. ">Sharief 1996</a>), where 23 adults were randomised to 400 mg per day topiramate and 24 were randomised to placebo. At the target dose, medication was administered twice daily. </p> <p>The parallel trial by <a href="./references#CD001417-bbs2-0010" title="TassinariC , ChauvelP , ChodkiewiczJ , ShorvonSD , HenriksenO , DamM , et al. Double‐blind, placebo‐controlled trial of 600 mg/day topiramate as add‐on therapy in patients with refractory partial epilepsy. Epilepsia1995;36(Suppl 3):S150. TassinariCA , MichelucciR , ChauvelP , ChodkiewiczJ , ShorvonS , HenriksenO , et al. Double‐blind, placebo‐controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia1996;37(8):763‐8. [PUBMED: 8764816] ">Tassinari 1996</a> was a multicentre trial in which adults were randomised to one of two treatments arms: 600 mg topiramate (n = 30) and placebo (n = 30). The baseline period was eight weeks followed by a treatment period of 12 weeks. </p> <p>One single‐centre, parallel trial in China had a baseline period of eight weeks and a treatment period of 14 weeks (<a href="./references#CD001417-bbs2-0011" title="YenDJ , YuHY , GuoYC , ChenC , YiuCH , SuMS . A double‐blind, placebo‐controlled study of topiramate in adult patients with refractory partial epilepsy. Epilepsia2000;41(9):1162‐6. [PUBMED: 10999555] ">Yen 2000</a>), and randomised 23 adults to 300 mg per day topiramate and 23 to placebo. </p> <p>One study included elderly patients (aged over 65) only and had two treatment arms (<a href="./references#CD001417-bbs2-0012" title="ZhangL , HuangJ , ZhuangJH , HuangLQ , ZhaoZX . Topiramate as an adjunctive treatment for refractory partial epilepsy in the elderly. Journal of International Medical Research2011;39(2):408‐15. [PUBMED: 21672344] ">Zhang 2011</a>): 200 mg per day topiramate (n = 46) or placebo (n = 40). The baseline period for this study was eight weeks in duration followed by a titration phase of eight weeks and then a treatment period of 12 weeks. </p> </section> <section id="CD001417-sec-0072"> <h4 class="title">Excluded studies</h4> <p>We excluded five RCTs for the following reasons: two studies had no placebo control group (<a href="./references#CD001417-bbs2-0013" title="ChristensenJ , AndreasenF , PoulsenJH , DamM . Randomized, concentration‐controlled trail of topiramate in refractory focal epilepsy. Neurology2003;61(9):1210‐8. [PUBMED: 14610122] ">Christensen 2003</a>; <a href="./references#CD001417-bbs2-0017" title="RamsayR , RowanA , SpitzM . Topiramate (TPM) in older adults with partial‐onset seizures: a double‐blind, dose‐comparison study. Epilepsia2005;46(Suppl 6):114, Abstract no: p235. RamsayRE ,  UthmanB , PryorFM , RowanAJ , BainbridgeJ ,  SpitzM ,  etal . Topiramate in older patients with partial‐onset seizures: a pilot double‐blind, dose‐comparison study. Epilepsia2008;49(7):1180‐5. [DOI: 10.1111/j.1528‐1167.2008.01584.x; PUBMED: 18494791] ">Ramsay 2008</a>), one study was an active comparator‐controlled trial (<a href="./references#CD001417-bbs2-0014" title="ChungSS , KerlsS , HammerA , KustraR . Cognitive effects of lamotrigine versus topiramate as adjunctive therapy in older adults with epilepsy. Neurology international2009;1(1):e6. [PUBMED: 21577364] ">Chung 2009</a>), one study had a baseline period of 48 hours (<a href="./references#CD001417-bbs2-0016" title="NovotnyE , RenfroeB , YardiN , NordliD , NessS , WangS , et al. Randomized trial of adjunctive topiramate therapy in infants with refractory partial seizures. Neurology2010;74(9):714‐20. [PUBMED: 20089937] RenfroeJB , NovotnyEJ , YardiN , NordliD , NessS , WangS , et al. A randomized, double‐blind, placebo‐controlled study of topiramate as an adjunct to anticonvulsant therapy in infants with refractory partial onset seizures. Epilepsia2008;49(Suppl 7):233, Abstract no: 2.140. ">Novotny 2010</a>), and one study did not investigate any of the outcomes under review (<a href="./references#CD001417-bbs2-0015" title="ColesH , BakerG , O'DonoghueM . Seizure severity in patients with partial onset (POS) or primary generalised tonic‐clonic (PGTC) seizures following treatment with topiramate. A comparison of two different methodologies in a randomised controlled trial. Epilepsia1999;40(Suppl 2):285. ">Coles 1999</a>). For further information regarding exclusion, see <a href="./references#CD001417-sec-0115" title="">Characteristics of excluded studies</a>. </p> <section id="CD001417-sec-0073"> <h5 class="title">Studies awaiting classification</h5> <p>We were unable to include a further two studies in the review as we unsure about their eligibility for inclusion (<a href="./references#CD001417-bbs2-0018" title="AranguizC , McJiltonJ , VegaM , RamsayR . Safety and effectiveness of three oral doses of topiramate in the treatment of patients with refractory partial epilepsy. Epilepsia1991;32(Suppl 3):11. ">Aranguiz 1991</a>; <a href="./references#CD001417-bbs2-0019" title="KazibutowskaZ , Stelmach‐WawrzyczekM . Efficacy of therapy with new antiepileptic drugs (tiagabine, gabapentin, topiramate) in drug‐resistant epilepsy. Epilepsia2000;41:38. ">Kazibutowska 2000</a>). We attempted to contact the authors for additional information to allow for the classification of the studies, but no correspondence had been received at the time of publication. For details regarding these studies, see <a href="./references#CD001417-sec-0116" title="">Characteristics of studies awaiting classification</a>. </p> </section> </section> </section> <section id="CD001417-sec-0074"> <h3 class="title">Risk of bias in included studies</h3> <p>We allocated each study a rating for each risk of bias domain. All studies included in the review were rated as having either low risk of bias or unclear risk of bias across all domains. Below, the specific domain ratings are explained. </p> <p>See 'Risk of bias' tables within the <a href="./references#CD001417-sec-0114" title="">Characteristics of included studies</a> tables for further details. See <a href="#CD001417-fig-0002">Figure 2</a> for a summary of the risk of bias in each included study and <a href="#CD001417-fig-0003">Figure 3</a> for a summary of each domain across studies. </p> <div class="figure" id="CD001417-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001417-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD001417-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001417-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD001417-sec-0075"> <h4 class="title">Allocation</h4> <p>For the domain of random sequence generation, we rated 11 studies as low risk of bias due to the use of a computer‐generated randomisation schedule or the use of random number tables/random permuted blocks (<a href="./references#CD001417-bbs2-0001" title="Ben‐MenachemE , DamM , HenriksenO , SchmidtD . Double‐blind, placebo‐controlled trial of 800 mg/day topiramate as add‐on therapy in patients with refractory partial epilepsy. Epilepsia1995;36(Suppl 3):S150. Ben‐MenachemE , DamM , MikkelsenM , EngelskjonT , HenriksenO , JohannessenS , et al. Topiramate add‐on treatment in patients with intractable partial epilepsy: a multicenter study. Epilepsia1993;34(Suppl 2):109. Ben‐MenachemE , HenriksenO , DamM , MikkelsenM , SchmidtD , ReidS , et al. Double‐blind, placebo‐controlled trial of topiramate as add‐on therapy in patients with refractory partial seizures. Epilepsia1996;37(6):539‐43. [PUBMED: 8641230] Martinez‐LageJ , Ben‐MenachemE , ShorvonSD , WeberM . Double‐blind, placebo‐controlled trial of 400 mg/day topiramate as add‐on therapy in patients with refractory partial epilepsy. Epilepsia1995;36(Suppl 3):S149‐50. OstergardL , DamM , MikkelsenM . Topiramate as add‐on therapy in refractory partial epilepsy. Epilepsia1992;33(Suppl 3):105. ">Ben‐Menachem 1996</a>; <a href="./references#CD001417-bbs2-0002" title="ArnoldS , BlattI , ClarkAM , HalvorsenMB , NagaraddiVN . USL255, a once‐daily, extended‐release topiramate, has positive effects on clinical outcomes and quality of life: results from the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):105, Abstract no: 1.223. BlattI , ChungSS , HoganRE , ClarkA , AndersB , HalvorsenM . Efficacy and safety of USL255, once‐daily extended‐release topiramate, in adults with partial onset seizures: the PREVAIL study. Epilepsia2014;55(Suppl 2):42‐43, Abstract no: p112. BlattI , NagaraddiV , HoganR , ArnoldS , LawsonB , AndersB , et al. Efficacy of USL255 across partial‐onset seizure types and refractory patient status: subgroup analyses from the PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.263. BlattI , NagaraddiVN , AndersB , ClarkAM , HalvorsenMB , HoganRE . USL255 is efficacious across all partial‐onset seizure types and with a variety of concomitant antiepileptic drugs: Results from subgroup analyses of the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):204, Abstract no: 2.116. ChungS . USL255 extended‐release topiramate for the treatment of epilepsy. Expert Review of Neurotherapeutics2014;14(10):1127‐37. [PUBMED: 25220748] ChungSS . A review of the efficacy and safety of extended‐release topiramate in the adjunctive treatment for refractory partial‐onset seizures. Therapeutic Advances in Neurological Disorders2015;8(3):131‐6. [PUBMED: 25941540] ChungSS , FakhouryTA , HoganRE , NagaraddiVN , BlattI , LawsonB , et al. Once‐daily USL255 as adjunctive treatment of partial‐onset seizures: randomized phase III study. Epilepsia2014;55(7):1077‐87. [PUBMED: 24902983] ChungSS , HoganR , BlattI , LawsonPB , NguyenH , ClarkAM , et al. Long‐term safety and sustained efficacy of USL255 (topiramate extended‐release capsules) in patients with refractory partial‐onset seizures. Epilepsy &amp; Behavior2016;59:13‐20. [PUBMED: 27084978] ClarkAM , ChungSS , BlattI , AndersB , HalvorsenMB , HoganRE . Efficacy of USL255 (qudexyTM XR; Extended‐release topiramate) in patients with refractory partial‐onset seizures: PREVAIL and PREVAIL OLE. Epilepsy Currents2015;15(Suppl 1):142‐3, Abstract no: 1.307. HoganR , ArnoldS , FakhouryT , AndersB . Adverse event profile of USL255 in patients with refractory partial‐onset seizures: the PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.262. HoganRE , ArnoldS , FakhouryTA , AndersB , LaineD , ToddWM , et al. Safety and tolerability of USL255 in subjects with refractory partial‐onset seizures: results from the randomized, phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):103‐4, Abstract no: 1.219. HoganRE , BlattI , LawsonB , NagaraddiV , FakhouryTA , AndersB , et al. Efficacy of once‐daily extended‐release topiramate (USL255): a subgroup analysis based on the level of treatment resistance. Epilepsy &amp; Behavior2014;41:136‐9. [PUBMED: 25461205] LawsonB , ChungSS , ClarkAM , HalvorsenMB , BlattI . Time to onset of efficacy and sustained treatment effects of USL255: results from the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):104, Abstract no: 1.222. NagaraddiV , ChungS , ArnoldS , ClarkA , AndersB , FakhouryT . Early onset of efficacy and safety outcomes with USL255 treatment: The PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.264. ">Chung 2014</a>; <a href="./references#CD001417-bbs2-0003" title="EltermanRD , GlauserTA , WyllieE , ReifeR , WuSC , PledgerG , et al. A double‐blind, randomized trial of topiramate as adjunctive therapy for partial‐onset seizures in children. Neurology1999;52(7):1338‐44. [PUBMED: 10227615] ">Elterman 1999</a>; <a href="./references#CD001417-bbs2-0004" title="FaughtE , WilderBJ , RamsayRE . Topiramate dose‐ranging trial in refractory partial epilepsy. Epilepsia1995;36(Suppl 4):33, Abstract no: D.9. FaughtE , WilderBJ , RamsayRE , ReifeRA , KramerLD , PledgerGW , et al. Topiramate placebo‐controlled dose‐ranging trial in refractory partial epilepsy using 200‐, 400‐, and 600‐mg daily dosages. Neurology1996;46(6):1684‐90. [PUBMED: 8649570] ">Faught 1996</a>; <a href="./references#CD001417-bbs2-0006" title="Korean Topiramate Study Group. Topiramate in medically intractable partial epilepsies: double‐blind placebo‐controlled randomized parallel group trial. Epilepsia1999;40(12):1767‐74. [PUBMED: 10612342] LeeBI . Double‐blind placebo‐controlled randomized clinical trial of topiramate add‐on therapy in medically intractable partial epilepsies. Journal of the Korean Neurology Association1998;16(6):809‐19. ">Korean Topiramate Study Group 1999</a>; <a href="./references#CD001417-bbs2-0007" title="PriviteraM , FinchamR , PenryJ , ReifeR , KramerL , PledgerG , et al. Topiramate placebo‐controlled dose‐ranging trial in refractory partial epilepsy using 600‐, 800‐, and 1,000‐mg daily dosages. Neurology1996;46(6):1678‐83. [PUBMED: 8649569] PriviteraM , FinchamR , PenryJK . Dose‐ranging trial with higher doses of topiramate in patients with resistant partial seizures. Epilepsia1995;36(Suppl 4):33, Abstract no: D.7. ">Privitera 1996</a>; <a href="./references#CD001417-bbs2-0008" title="RosenfeldW , Abou‐KhalilB , ReifeR , HegadusR , PledgerG , Topiramate YF/YG Study Group. Placebo‐controlled trial of topiramate as adjunctive therapy to carbamazepine or phenytoin for partial‐onset seizures. Epilepsia1996;37(Suppl 5):153, Abstract no: 6.7. ">Rosenfeld 1996</a>; <a href="./references#CD001417-bbs2-0009" title="ShariefM , ViteriC , Ben‐MenachemE , WeberM , ReifeR , PledgerG , et al. Double‐blind, placebo‐controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Research1996;25(3):217‐24. [PUBMED: 8956919] ShariefMK , SanderJW , PatsalosPN , ShorvonSD . Adjuvant topiramate treatment in intractable partial epilepsy. Epilepsia1993;6:41. ">Sharief 1996</a>; <a href="./references#CD001417-bbs2-0010" title="TassinariC , ChauvelP , ChodkiewiczJ , ShorvonSD , HenriksenO , DamM , et al. Double‐blind, placebo‐controlled trial of 600 mg/day topiramate as add‐on therapy in patients with refractory partial epilepsy. Epilepsia1995;36(Suppl 3):S150. TassinariCA , MichelucciR , ChauvelP , ChodkiewiczJ , ShorvonS , HenriksenO , et al. Double‐blind, placebo‐controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia1996;37(8):763‐8. [PUBMED: 8764816] ">Tassinari 1996</a>; <a href="./references#CD001417-bbs2-0011" title="YenDJ , YuHY , GuoYC , ChenC , YiuCH , SuMS . A double‐blind, placebo‐controlled study of topiramate in adult patients with refractory partial epilepsy. Epilepsia2000;41(9):1162‐6. [PUBMED: 10999555] ">Yen 2000</a>; <a href="./references#CD001417-bbs2-0012" title="ZhangL , HuangJ , ZhuangJH , HuangLQ , ZhaoZX . Topiramate as an adjunctive treatment for refractory partial epilepsy in the elderly. Journal of International Medical Research2011;39(2):408‐15. [PUBMED: 21672344] ">Zhang 2011</a>). We rated one study as unclear due to a lack of detail provided regarding the methods used (<a href="./references#CD001417-bbs2-0005" title="GubermanA , NetoW , Gassmann‐MayerC , EPAJ‐119 Study Group. Low‐dose topiramate in adults with treatment‐resistant partial‐onset seizures. Acta Neurologica Scandinavica2002;106(4):183‐9. [PUBMED: 12225311] GubermanA , NetoW , Gassmann‐MayerC , Topiramate EPAJ‐119 Study Group. Efficacy of 200 mg/day topiramate in treatment‐resistant partial seizures when added to an enzyme‐inducing anti‐epileptic drug (AED). Epilepsia2001;42(Suppl 7):179‐80, Abstract no: 2.244. NetoW , Gassmann‐MayerC , Topiramate EPAJ‐119 study group. Efficacy and tolerability of 200 mg/day topiramate in a placebo‐controlled comparison of titration rates. Epilepsia2000;41:35. VanOeneJ , NetoW , NilssonJ , HamiltonG , BaetenB , SchreinerA , et al. Weight reduction during topiramate treatment of partial seizures. Epilepsia2002;43(Suppl 8):152, Abstract no: P482. ">Guberman 2002</a>). </p> <p>In addition, we rated the methods by which allocation was concealed in 10 of the included studies as low risk of bias (<a href="./references#CD001417-bbs2-0001" title="Ben‐MenachemE , DamM , HenriksenO , SchmidtD . Double‐blind, placebo‐controlled trial of 800 mg/day topiramate as add‐on therapy in patients with refractory partial epilepsy. Epilepsia1995;36(Suppl 3):S150. Ben‐MenachemE , DamM , MikkelsenM , EngelskjonT , HenriksenO , JohannessenS , et al. Topiramate add‐on treatment in patients with intractable partial epilepsy: a multicenter study. Epilepsia1993;34(Suppl 2):109. Ben‐MenachemE , HenriksenO , DamM , MikkelsenM , SchmidtD , ReidS , et al. Double‐blind, placebo‐controlled trial of topiramate as add‐on therapy in patients with refractory partial seizures. Epilepsia1996;37(6):539‐43. [PUBMED: 8641230] Martinez‐LageJ , Ben‐MenachemE , ShorvonSD , WeberM . Double‐blind, placebo‐controlled trial of 400 mg/day topiramate as add‐on therapy in patients with refractory partial epilepsy. Epilepsia1995;36(Suppl 3):S149‐50. OstergardL , DamM , MikkelsenM . Topiramate as add‐on therapy in refractory partial epilepsy. Epilepsia1992;33(Suppl 3):105. ">Ben‐Menachem 1996</a>; <a href="./references#CD001417-bbs2-0002" title="ArnoldS , BlattI , ClarkAM , HalvorsenMB , NagaraddiVN . USL255, a once‐daily, extended‐release topiramate, has positive effects on clinical outcomes and quality of life: results from the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):105, Abstract no: 1.223. BlattI , ChungSS , HoganRE , ClarkA , AndersB , HalvorsenM . Efficacy and safety of USL255, once‐daily extended‐release topiramate, in adults with partial onset seizures: the PREVAIL study. Epilepsia2014;55(Suppl 2):42‐43, Abstract no: p112. BlattI , NagaraddiV , HoganR , ArnoldS , LawsonB , AndersB , et al. Efficacy of USL255 across partial‐onset seizure types and refractory patient status: subgroup analyses from the PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.263. BlattI , NagaraddiVN , AndersB , ClarkAM , HalvorsenMB , HoganRE . USL255 is efficacious across all partial‐onset seizure types and with a variety of concomitant antiepileptic drugs: Results from subgroup analyses of the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):204, Abstract no: 2.116. ChungS . USL255 extended‐release topiramate for the treatment of epilepsy. Expert Review of Neurotherapeutics2014;14(10):1127‐37. [PUBMED: 25220748] ChungSS . A review of the efficacy and safety of extended‐release topiramate in the adjunctive treatment for refractory partial‐onset seizures. Therapeutic Advances in Neurological Disorders2015;8(3):131‐6. [PUBMED: 25941540] ChungSS , FakhouryTA , HoganRE , NagaraddiVN , BlattI , LawsonB , et al. Once‐daily USL255 as adjunctive treatment of partial‐onset seizures: randomized phase III study. Epilepsia2014;55(7):1077‐87. [PUBMED: 24902983] ChungSS , HoganR , BlattI , LawsonPB , NguyenH , ClarkAM , et al. Long‐term safety and sustained efficacy of USL255 (topiramate extended‐release capsules) in patients with refractory partial‐onset seizures. Epilepsy &amp; Behavior2016;59:13‐20. [PUBMED: 27084978] ClarkAM , ChungSS , BlattI , AndersB , HalvorsenMB , HoganRE . Efficacy of USL255 (qudexyTM XR; Extended‐release topiramate) in patients with refractory partial‐onset seizures: PREVAIL and PREVAIL OLE. Epilepsy Currents2015;15(Suppl 1):142‐3, Abstract no: 1.307. HoganR , ArnoldS , FakhouryT , AndersB . Adverse event profile of USL255 in patients with refractory partial‐onset seizures: the PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.262. HoganRE , ArnoldS , FakhouryTA , AndersB , LaineD , ToddWM , et al. Safety and tolerability of USL255 in subjects with refractory partial‐onset seizures: results from the randomized, phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):103‐4, Abstract no: 1.219. HoganRE , BlattI , LawsonB , NagaraddiV , FakhouryTA , AndersB , et al. Efficacy of once‐daily extended‐release topiramate (USL255): a subgroup analysis based on the level of treatment resistance. Epilepsy &amp; Behavior2014;41:136‐9. [PUBMED: 25461205] LawsonB , ChungSS , ClarkAM , HalvorsenMB , BlattI . Time to onset of efficacy and sustained treatment effects of USL255: results from the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):104, Abstract no: 1.222. NagaraddiV , ChungS , ArnoldS , ClarkA , AndersB , FakhouryT . Early onset of efficacy and safety outcomes with USL255 treatment: The PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.264. ">Chung 2014</a>; <a href="./references#CD001417-bbs2-0003" title="EltermanRD , GlauserTA , WyllieE , ReifeR , WuSC , PledgerG , et al. A double‐blind, randomized trial of topiramate as adjunctive therapy for partial‐onset seizures in children. Neurology1999;52(7):1338‐44. [PUBMED: 10227615] ">Elterman 1999</a>; <a href="./references#CD001417-bbs2-0004" title="FaughtE , WilderBJ , RamsayRE . Topiramate dose‐ranging trial in refractory partial epilepsy. Epilepsia1995;36(Suppl 4):33, Abstract no: D.9. FaughtE , WilderBJ , RamsayRE , ReifeRA , KramerLD , PledgerGW , et al. Topiramate placebo‐controlled dose‐ranging trial in refractory partial epilepsy using 200‐, 400‐, and 600‐mg daily dosages. Neurology1996;46(6):1684‐90. [PUBMED: 8649570] ">Faught 1996</a>; <a href="./references#CD001417-bbs2-0006" title="Korean Topiramate Study Group. Topiramate in medically intractable partial epilepsies: double‐blind placebo‐controlled randomized parallel group trial. Epilepsia1999;40(12):1767‐74. [PUBMED: 10612342] LeeBI . Double‐blind placebo‐controlled randomized clinical trial of topiramate add‐on therapy in medically intractable partial epilepsies. Journal of the Korean Neurology Association1998;16(6):809‐19. ">Korean Topiramate Study Group 1999</a>; <a href="./references#CD001417-bbs2-0007" title="PriviteraM , FinchamR , PenryJ , ReifeR , KramerL , PledgerG , et al. Topiramate placebo‐controlled dose‐ranging trial in refractory partial epilepsy using 600‐, 800‐, and 1,000‐mg daily dosages. Neurology1996;46(6):1678‐83. [PUBMED: 8649569] PriviteraM , FinchamR , PenryJK . Dose‐ranging trial with higher doses of topiramate in patients with resistant partial seizures. Epilepsia1995;36(Suppl 4):33, Abstract no: D.7. ">Privitera 1996</a>; <a href="./references#CD001417-bbs2-0008" title="RosenfeldW , Abou‐KhalilB , ReifeR , HegadusR , PledgerG , Topiramate YF/YG Study Group. Placebo‐controlled trial of topiramate as adjunctive therapy to carbamazepine or phenytoin for partial‐onset seizures. Epilepsia1996;37(Suppl 5):153, Abstract no: 6.7. ">Rosenfeld 1996</a>; <a href="./references#CD001417-bbs2-0009" title="ShariefM , ViteriC , Ben‐MenachemE , WeberM , ReifeR , PledgerG , et al. Double‐blind, placebo‐controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Research1996;25(3):217‐24. [PUBMED: 8956919] ShariefMK , SanderJW , PatsalosPN , ShorvonSD . Adjuvant topiramate treatment in intractable partial epilepsy. Epilepsia1993;6:41. ">Sharief 1996</a>; <a href="./references#CD001417-bbs2-0010" title="TassinariC , ChauvelP , ChodkiewiczJ , ShorvonSD , HenriksenO , DamM , et al. Double‐blind, placebo‐controlled trial of 600 mg/day topiramate as add‐on therapy in patients with refractory partial epilepsy. Epilepsia1995;36(Suppl 3):S150. TassinariCA , MichelucciR , ChauvelP , ChodkiewiczJ , ShorvonS , HenriksenO , et al. Double‐blind, placebo‐controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia1996;37(8):763‐8. [PUBMED: 8764816] ">Tassinari 1996</a>; <a href="./references#CD001417-bbs2-0011" title="YenDJ , YuHY , GuoYC , ChenC , YiuCH , SuMS . A double‐blind, placebo‐controlled study of topiramate in adult patients with refractory partial epilepsy. Epilepsia2000;41(9):1162‐6. [PUBMED: 10999555] ">Yen 2000</a>). Nine of the studies used sealed, numbered packages, allocated sequentially, to conceal allocation (<a href="./references#CD001417-bbs2-0001" title="Ben‐MenachemE , DamM , HenriksenO , SchmidtD . Double‐blind, placebo‐controlled trial of 800 mg/day topiramate as add‐on therapy in patients with refractory partial epilepsy. Epilepsia1995;36(Suppl 3):S150. Ben‐MenachemE , DamM , MikkelsenM , EngelskjonT , HenriksenO , JohannessenS , et al. Topiramate add‐on treatment in patients with intractable partial epilepsy: a multicenter study. Epilepsia1993;34(Suppl 2):109. Ben‐MenachemE , HenriksenO , DamM , MikkelsenM , SchmidtD , ReidS , et al. Double‐blind, placebo‐controlled trial of topiramate as add‐on therapy in patients with refractory partial seizures. Epilepsia1996;37(6):539‐43. [PUBMED: 8641230] Martinez‐LageJ , Ben‐MenachemE , ShorvonSD , WeberM . Double‐blind, placebo‐controlled trial of 400 mg/day topiramate as add‐on therapy in patients with refractory partial epilepsy. Epilepsia1995;36(Suppl 3):S149‐50. OstergardL , DamM , MikkelsenM . Topiramate as add‐on therapy in refractory partial epilepsy. Epilepsia1992;33(Suppl 3):105. ">Ben‐Menachem 1996</a>; <a href="./references#CD001417-bbs2-0003" title="EltermanRD , GlauserTA , WyllieE , ReifeR , WuSC , PledgerG , et al. A double‐blind, randomized trial of topiramate as adjunctive therapy for partial‐onset seizures in children. Neurology1999;52(7):1338‐44. [PUBMED: 10227615] ">Elterman 1999</a>; <a href="./references#CD001417-bbs2-0004" title="FaughtE , WilderBJ , RamsayRE . Topiramate dose‐ranging trial in refractory partial epilepsy. Epilepsia1995;36(Suppl 4):33, Abstract no: D.9. FaughtE , WilderBJ , RamsayRE , ReifeRA , KramerLD , PledgerGW , et al. Topiramate placebo‐controlled dose‐ranging trial in refractory partial epilepsy using 200‐, 400‐, and 600‐mg daily dosages. Neurology1996;46(6):1684‐90. [PUBMED: 8649570] ">Faught 1996</a>; <a href="./references#CD001417-bbs2-0006" title="Korean Topiramate Study Group. Topiramate in medically intractable partial epilepsies: double‐blind placebo‐controlled randomized parallel group trial. Epilepsia1999;40(12):1767‐74. [PUBMED: 10612342] LeeBI . Double‐blind placebo‐controlled randomized clinical trial of topiramate add‐on therapy in medically intractable partial epilepsies. Journal of the Korean Neurology Association1998;16(6):809‐19. ">Korean Topiramate Study Group 1999</a>; <a href="./references#CD001417-bbs2-0007" title="PriviteraM , FinchamR , PenryJ , ReifeR , KramerL , PledgerG , et al. Topiramate placebo‐controlled dose‐ranging trial in refractory partial epilepsy using 600‐, 800‐, and 1,000‐mg daily dosages. Neurology1996;46(6):1678‐83. [PUBMED: 8649569] PriviteraM , FinchamR , PenryJK . Dose‐ranging trial with higher doses of topiramate in patients with resistant partial seizures. Epilepsia1995;36(Suppl 4):33, Abstract no: D.7. ">Privitera 1996</a>; <a href="./references#CD001417-bbs2-0008" title="RosenfeldW , Abou‐KhalilB , ReifeR , HegadusR , PledgerG , Topiramate YF/YG Study Group. Placebo‐controlled trial of topiramate as adjunctive therapy to carbamazepine or phenytoin for partial‐onset seizures. Epilepsia1996;37(Suppl 5):153, Abstract no: 6.7. ">Rosenfeld 1996</a>; <a href="./references#CD001417-bbs2-0009" title="ShariefM , ViteriC , Ben‐MenachemE , WeberM , ReifeR , PledgerG , et al. Double‐blind, placebo‐controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Research1996;25(3):217‐24. [PUBMED: 8956919] ShariefMK , SanderJW , PatsalosPN , ShorvonSD . Adjuvant topiramate treatment in intractable partial epilepsy. Epilepsia1993;6:41. ">Sharief 1996</a>; <a href="./references#CD001417-bbs2-0010" title="TassinariC , ChauvelP , ChodkiewiczJ , ShorvonSD , HenriksenO , DamM , et al. Double‐blind, placebo‐controlled trial of 600 mg/day topiramate as add‐on therapy in patients with refractory partial epilepsy. Epilepsia1995;36(Suppl 3):S150. TassinariCA , MichelucciR , ChauvelP , ChodkiewiczJ , ShorvonS , HenriksenO , et al. Double‐blind, placebo‐controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia1996;37(8):763‐8. [PUBMED: 8764816] ">Tassinari 1996</a>; <a href="./references#CD001417-bbs2-0011" title="YenDJ , YuHY , GuoYC , ChenC , YiuCH , SuMS . A double‐blind, placebo‐controlled study of topiramate in adult patients with refractory partial epilepsy. Epilepsia2000;41(9):1162‐6. [PUBMED: 10999555] ">Yen 2000</a>), and one more recent trial used an interactive voice response system (<a href="./references#CD001417-bbs2-0002" title="ArnoldS , BlattI , ClarkAM , HalvorsenMB , NagaraddiVN . USL255, a once‐daily, extended‐release topiramate, has positive effects on clinical outcomes and quality of life: results from the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):105, Abstract no: 1.223. BlattI , ChungSS , HoganRE , ClarkA , AndersB , HalvorsenM . Efficacy and safety of USL255, once‐daily extended‐release topiramate, in adults with partial onset seizures: the PREVAIL study. Epilepsia2014;55(Suppl 2):42‐43, Abstract no: p112. BlattI , NagaraddiV , HoganR , ArnoldS , LawsonB , AndersB , et al. Efficacy of USL255 across partial‐onset seizure types and refractory patient status: subgroup analyses from the PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.263. BlattI , NagaraddiVN , AndersB , ClarkAM , HalvorsenMB , HoganRE . USL255 is efficacious across all partial‐onset seizure types and with a variety of concomitant antiepileptic drugs: Results from subgroup analyses of the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):204, Abstract no: 2.116. ChungS . USL255 extended‐release topiramate for the treatment of epilepsy. Expert Review of Neurotherapeutics2014;14(10):1127‐37. [PUBMED: 25220748] ChungSS . A review of the efficacy and safety of extended‐release topiramate in the adjunctive treatment for refractory partial‐onset seizures. Therapeutic Advances in Neurological Disorders2015;8(3):131‐6. [PUBMED: 25941540] ChungSS , FakhouryTA , HoganRE , NagaraddiVN , BlattI , LawsonB , et al. Once‐daily USL255 as adjunctive treatment of partial‐onset seizures: randomized phase III study. Epilepsia2014;55(7):1077‐87. [PUBMED: 24902983] ChungSS , HoganR , BlattI , LawsonPB , NguyenH , ClarkAM , et al. Long‐term safety and sustained efficacy of USL255 (topiramate extended‐release capsules) in patients with refractory partial‐onset seizures. Epilepsy &amp; Behavior2016;59:13‐20. [PUBMED: 27084978] ClarkAM , ChungSS , BlattI , AndersB , HalvorsenMB , HoganRE . Efficacy of USL255 (qudexyTM XR; Extended‐release topiramate) in patients with refractory partial‐onset seizures: PREVAIL and PREVAIL OLE. Epilepsy Currents2015;15(Suppl 1):142‐3, Abstract no: 1.307. HoganR , ArnoldS , FakhouryT , AndersB . Adverse event profile of USL255 in patients with refractory partial‐onset seizures: the PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.262. HoganRE , ArnoldS , FakhouryTA , AndersB , LaineD , ToddWM , et al. Safety and tolerability of USL255 in subjects with refractory partial‐onset seizures: results from the randomized, phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):103‐4, Abstract no: 1.219. HoganRE , BlattI , LawsonB , NagaraddiV , FakhouryTA , AndersB , et al. Efficacy of once‐daily extended‐release topiramate (USL255): a subgroup analysis based on the level of treatment resistance. Epilepsy &amp; Behavior2014;41:136‐9. [PUBMED: 25461205] LawsonB , ChungSS , ClarkAM , HalvorsenMB , BlattI . Time to onset of efficacy and sustained treatment effects of USL255: results from the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):104, Abstract no: 1.222. NagaraddiV , ChungS , ArnoldS , ClarkA , AndersB , FakhouryT . Early onset of efficacy and safety outcomes with USL255 treatment: The PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.264. ">Chung 2014</a>). Two trials did not provide clear methods and we thus rated them as having unclear risk of bias for this domain (<a href="./references#CD001417-bbs2-0005" title="GubermanA , NetoW , Gassmann‐MayerC , EPAJ‐119 Study Group. Low‐dose topiramate in adults with treatment‐resistant partial‐onset seizures. Acta Neurologica Scandinavica2002;106(4):183‐9. [PUBMED: 12225311] GubermanA , NetoW , Gassmann‐MayerC , Topiramate EPAJ‐119 Study Group. Efficacy of 200 mg/day topiramate in treatment‐resistant partial seizures when added to an enzyme‐inducing anti‐epileptic drug (AED). Epilepsia2001;42(Suppl 7):179‐80, Abstract no: 2.244. NetoW , Gassmann‐MayerC , Topiramate EPAJ‐119 study group. Efficacy and tolerability of 200 mg/day topiramate in a placebo‐controlled comparison of titration rates. Epilepsia2000;41:35. VanOeneJ , NetoW , NilssonJ , HamiltonG , BaetenB , SchreinerA , et al. Weight reduction during topiramate treatment of partial seizures. Epilepsia2002;43(Suppl 8):152, Abstract no: P482. ">Guberman 2002</a>; <a href="./references#CD001417-bbs2-0012" title="ZhangL , HuangJ , ZhuangJH , HuangLQ , ZhaoZX . Topiramate as an adjunctive treatment for refractory partial epilepsy in the elderly. Journal of International Medical Research2011;39(2):408‐15. [PUBMED: 21672344] ">Zhang 2011</a>). </p> </section> <section id="CD001417-sec-0076"> <h4 class="title">Blinding</h4> <p>In all but one study, successful blinding of participants was achieved by using identical medication within the topiramate and placebo groups (<a href="./references#CD001417-bbs2-0001" title="Ben‐MenachemE , DamM , HenriksenO , SchmidtD . Double‐blind, placebo‐controlled trial of 800 mg/day topiramate as add‐on therapy in patients with refractory partial epilepsy. Epilepsia1995;36(Suppl 3):S150. Ben‐MenachemE , DamM , MikkelsenM , EngelskjonT , HenriksenO , JohannessenS , et al. Topiramate add‐on treatment in patients with intractable partial epilepsy: a multicenter study. Epilepsia1993;34(Suppl 2):109. Ben‐MenachemE , HenriksenO , DamM , MikkelsenM , SchmidtD , ReidS , et al. Double‐blind, placebo‐controlled trial of topiramate as add‐on therapy in patients with refractory partial seizures. Epilepsia1996;37(6):539‐43. [PUBMED: 8641230] Martinez‐LageJ , Ben‐MenachemE , ShorvonSD , WeberM . Double‐blind, placebo‐controlled trial of 400 mg/day topiramate as add‐on therapy in patients with refractory partial epilepsy. Epilepsia1995;36(Suppl 3):S149‐50. OstergardL , DamM , MikkelsenM . Topiramate as add‐on therapy in refractory partial epilepsy. Epilepsia1992;33(Suppl 3):105. ">Ben‐Menachem 1996</a>; <a href="./references#CD001417-bbs2-0002" title="ArnoldS , BlattI , ClarkAM , HalvorsenMB , NagaraddiVN . USL255, a once‐daily, extended‐release topiramate, has positive effects on clinical outcomes and quality of life: results from the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):105, Abstract no: 1.223. BlattI , ChungSS , HoganRE , ClarkA , AndersB , HalvorsenM . Efficacy and safety of USL255, once‐daily extended‐release topiramate, in adults with partial onset seizures: the PREVAIL study. Epilepsia2014;55(Suppl 2):42‐43, Abstract no: p112. BlattI , NagaraddiV , HoganR , ArnoldS , LawsonB , AndersB , et al. Efficacy of USL255 across partial‐onset seizure types and refractory patient status: subgroup analyses from the PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.263. BlattI , NagaraddiVN , AndersB , ClarkAM , HalvorsenMB , HoganRE . USL255 is efficacious across all partial‐onset seizure types and with a variety of concomitant antiepileptic drugs: Results from subgroup analyses of the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):204, Abstract no: 2.116. ChungS . USL255 extended‐release topiramate for the treatment of epilepsy. Expert Review of Neurotherapeutics2014;14(10):1127‐37. [PUBMED: 25220748] ChungSS . A review of the efficacy and safety of extended‐release topiramate in the adjunctive treatment for refractory partial‐onset seizures. Therapeutic Advances in Neurological Disorders2015;8(3):131‐6. [PUBMED: 25941540] ChungSS , FakhouryTA , HoganRE , NagaraddiVN , BlattI , LawsonB , et al. Once‐daily USL255 as adjunctive treatment of partial‐onset seizures: randomized phase III study. Epilepsia2014;55(7):1077‐87. [PUBMED: 24902983] ChungSS , HoganR , BlattI , LawsonPB , NguyenH , ClarkAM , et al. Long‐term safety and sustained efficacy of USL255 (topiramate extended‐release capsules) in patients with refractory partial‐onset seizures. Epilepsy &amp; Behavior2016;59:13‐20. [PUBMED: 27084978] ClarkAM , ChungSS , BlattI , AndersB , HalvorsenMB , HoganRE . Efficacy of USL255 (qudexyTM XR; Extended‐release topiramate) in patients with refractory partial‐onset seizures: PREVAIL and PREVAIL OLE. Epilepsy Currents2015;15(Suppl 1):142‐3, Abstract no: 1.307. HoganR , ArnoldS , FakhouryT , AndersB . Adverse event profile of USL255 in patients with refractory partial‐onset seizures: the PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.262. HoganRE , ArnoldS , FakhouryTA , AndersB , LaineD , ToddWM , et al. Safety and tolerability of USL255 in subjects with refractory partial‐onset seizures: results from the randomized, phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):103‐4, Abstract no: 1.219. HoganRE , BlattI , LawsonB , NagaraddiV , FakhouryTA , AndersB , et al. Efficacy of once‐daily extended‐release topiramate (USL255): a subgroup analysis based on the level of treatment resistance. Epilepsy &amp; Behavior2014;41:136‐9. [PUBMED: 25461205] LawsonB , ChungSS , ClarkAM , HalvorsenMB , BlattI . Time to onset of efficacy and sustained treatment effects of USL255: results from the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):104, Abstract no: 1.222. NagaraddiV , ChungS , ArnoldS , ClarkA , AndersB , FakhouryT . Early onset of efficacy and safety outcomes with USL255 treatment: The PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.264. ">Chung 2014</a>; <a href="./references#CD001417-bbs2-0003" title="EltermanRD , GlauserTA , WyllieE , ReifeR , WuSC , PledgerG , et al. A double‐blind, randomized trial of topiramate as adjunctive therapy for partial‐onset seizures in children. Neurology1999;52(7):1338‐44. [PUBMED: 10227615] ">Elterman 1999</a>; <a href="./references#CD001417-bbs2-0004" title="FaughtE , WilderBJ , RamsayRE . Topiramate dose‐ranging trial in refractory partial epilepsy. Epilepsia1995;36(Suppl 4):33, Abstract no: D.9. FaughtE , WilderBJ , RamsayRE , ReifeRA , KramerLD , PledgerGW , et al. Topiramate placebo‐controlled dose‐ranging trial in refractory partial epilepsy using 200‐, 400‐, and 600‐mg daily dosages. Neurology1996;46(6):1684‐90. [PUBMED: 8649570] ">Faught 1996</a>; <a href="./references#CD001417-bbs2-0005" title="GubermanA , NetoW , Gassmann‐MayerC , EPAJ‐119 Study Group. Low‐dose topiramate in adults with treatment‐resistant partial‐onset seizures. Acta Neurologica Scandinavica2002;106(4):183‐9. [PUBMED: 12225311] GubermanA , NetoW , Gassmann‐MayerC , Topiramate EPAJ‐119 Study Group. Efficacy of 200 mg/day topiramate in treatment‐resistant partial seizures when added to an enzyme‐inducing anti‐epileptic drug (AED). Epilepsia2001;42(Suppl 7):179‐80, Abstract no: 2.244. NetoW , Gassmann‐MayerC , Topiramate EPAJ‐119 study group. Efficacy and tolerability of 200 mg/day topiramate in a placebo‐controlled comparison of titration rates. Epilepsia2000;41:35. VanOeneJ , NetoW , NilssonJ , HamiltonG , BaetenB , SchreinerA , et al. Weight reduction during topiramate treatment of partial seizures. Epilepsia2002;43(Suppl 8):152, Abstract no: P482. ">Guberman 2002</a>; <a href="./references#CD001417-bbs2-0006" title="Korean Topiramate Study Group. Topiramate in medically intractable partial epilepsies: double‐blind placebo‐controlled randomized parallel group trial. Epilepsia1999;40(12):1767‐74. [PUBMED: 10612342] LeeBI . Double‐blind placebo‐controlled randomized clinical trial of topiramate add‐on therapy in medically intractable partial epilepsies. Journal of the Korean Neurology Association1998;16(6):809‐19. ">Korean Topiramate Study Group 1999</a>; <a href="./references#CD001417-bbs2-0007" title="PriviteraM , FinchamR , PenryJ , ReifeR , KramerL , PledgerG , et al. Topiramate placebo‐controlled dose‐ranging trial in refractory partial epilepsy using 600‐, 800‐, and 1,000‐mg daily dosages. Neurology1996;46(6):1678‐83. [PUBMED: 8649569] PriviteraM , FinchamR , PenryJK . Dose‐ranging trial with higher doses of topiramate in patients with resistant partial seizures. Epilepsia1995;36(Suppl 4):33, Abstract no: D.7. ">Privitera 1996</a>; <a href="./references#CD001417-bbs2-0008" title="RosenfeldW , Abou‐KhalilB , ReifeR , HegadusR , PledgerG , Topiramate YF/YG Study Group. Placebo‐controlled trial of topiramate as adjunctive therapy to carbamazepine or phenytoin for partial‐onset seizures. Epilepsia1996;37(Suppl 5):153, Abstract no: 6.7. ">Rosenfeld 1996</a>; <a href="./references#CD001417-bbs2-0009" title="ShariefM , ViteriC , Ben‐MenachemE , WeberM , ReifeR , PledgerG , et al. Double‐blind, placebo‐controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Research1996;25(3):217‐24. [PUBMED: 8956919] ShariefMK , SanderJW , PatsalosPN , ShorvonSD . Adjuvant topiramate treatment in intractable partial epilepsy. Epilepsia1993;6:41. ">Sharief 1996</a>; <a href="./references#CD001417-bbs2-0010" title="TassinariC , ChauvelP , ChodkiewiczJ , ShorvonSD , HenriksenO , DamM , et al. Double‐blind, placebo‐controlled trial of 600 mg/day topiramate as add‐on therapy in patients with refractory partial epilepsy. Epilepsia1995;36(Suppl 3):S150. TassinariCA , MichelucciR , ChauvelP , ChodkiewiczJ , ShorvonS , HenriksenO , et al. Double‐blind, placebo‐controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia1996;37(8):763‐8. [PUBMED: 8764816] ">Tassinari 1996</a>; <a href="./references#CD001417-bbs2-0011" title="YenDJ , YuHY , GuoYC , ChenC , YiuCH , SuMS . A double‐blind, placebo‐controlled study of topiramate in adult patients with refractory partial epilepsy. Epilepsia2000;41(9):1162‐6. [PUBMED: 10999555] ">Yen 2000</a>); we judged these 11 studies at low risk of performance bias. There were no details reported by <a href="./references#CD001417-bbs2-0012" title="ZhangL , HuangJ , ZhuangJH , HuangLQ , ZhaoZX . Topiramate as an adjunctive treatment for refractory partial epilepsy in the elderly. Journal of International Medical Research2011;39(2):408‐15. [PUBMED: 21672344] ">Zhang 2011</a>, and so we rated this study as having unclear risk of bias. The blinding of the outcome assessor was difficult to judge due to the lack of detail in 10 of the publications (<a href="./references#CD001417-bbs2-0001" title="Ben‐MenachemE , DamM , HenriksenO , SchmidtD . Double‐blind, placebo‐controlled trial of 800 mg/day topiramate as add‐on therapy in patients with refractory partial epilepsy. Epilepsia1995;36(Suppl 3):S150. Ben‐MenachemE , DamM , MikkelsenM , EngelskjonT , HenriksenO , JohannessenS , et al. Topiramate add‐on treatment in patients with intractable partial epilepsy: a multicenter study. Epilepsia1993;34(Suppl 2):109. Ben‐MenachemE , HenriksenO , DamM , MikkelsenM , SchmidtD , ReidS , et al. Double‐blind, placebo‐controlled trial of topiramate as add‐on therapy in patients with refractory partial seizures. Epilepsia1996;37(6):539‐43. [PUBMED: 8641230] Martinez‐LageJ , Ben‐MenachemE , ShorvonSD , WeberM . Double‐blind, placebo‐controlled trial of 400 mg/day topiramate as add‐on therapy in patients with refractory partial epilepsy. Epilepsia1995;36(Suppl 3):S149‐50. OstergardL , DamM , MikkelsenM . Topiramate as add‐on therapy in refractory partial epilepsy. Epilepsia1992;33(Suppl 3):105. ">Ben‐Menachem 1996</a>; <a href="./references#CD001417-bbs2-0002" title="ArnoldS , BlattI , ClarkAM , HalvorsenMB , NagaraddiVN . USL255, a once‐daily, extended‐release topiramate, has positive effects on clinical outcomes and quality of life: results from the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):105, Abstract no: 1.223. BlattI , ChungSS , HoganRE , ClarkA , AndersB , HalvorsenM . Efficacy and safety of USL255, once‐daily extended‐release topiramate, in adults with partial onset seizures: the PREVAIL study. Epilepsia2014;55(Suppl 2):42‐43, Abstract no: p112. BlattI , NagaraddiV , HoganR , ArnoldS , LawsonB , AndersB , et al. Efficacy of USL255 across partial‐onset seizure types and refractory patient status: subgroup analyses from the PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.263. BlattI , NagaraddiVN , AndersB , ClarkAM , HalvorsenMB , HoganRE . USL255 is efficacious across all partial‐onset seizure types and with a variety of concomitant antiepileptic drugs: Results from subgroup analyses of the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):204, Abstract no: 2.116. ChungS . USL255 extended‐release topiramate for the treatment of epilepsy. Expert Review of Neurotherapeutics2014;14(10):1127‐37. [PUBMED: 25220748] ChungSS . A review of the efficacy and safety of extended‐release topiramate in the adjunctive treatment for refractory partial‐onset seizures. Therapeutic Advances in Neurological Disorders2015;8(3):131‐6. [PUBMED: 25941540] ChungSS , FakhouryTA , HoganRE , NagaraddiVN , BlattI , LawsonB , et al. Once‐daily USL255 as adjunctive treatment of partial‐onset seizures: randomized phase III study. Epilepsia2014;55(7):1077‐87. [PUBMED: 24902983] ChungSS , HoganR , BlattI , LawsonPB , NguyenH , ClarkAM , et al. Long‐term safety and sustained efficacy of USL255 (topiramate extended‐release capsules) in patients with refractory partial‐onset seizures. Epilepsy &amp; Behavior2016;59:13‐20. [PUBMED: 27084978] ClarkAM , ChungSS , BlattI , AndersB , HalvorsenMB , HoganRE . Efficacy of USL255 (qudexyTM XR; Extended‐release topiramate) in patients with refractory partial‐onset seizures: PREVAIL and PREVAIL OLE. Epilepsy Currents2015;15(Suppl 1):142‐3, Abstract no: 1.307. HoganR , ArnoldS , FakhouryT , AndersB . Adverse event profile of USL255 in patients with refractory partial‐onset seizures: the PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.262. HoganRE , ArnoldS , FakhouryTA , AndersB , LaineD , ToddWM , et al. Safety and tolerability of USL255 in subjects with refractory partial‐onset seizures: results from the randomized, phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):103‐4, Abstract no: 1.219. HoganRE , BlattI , LawsonB , NagaraddiV , FakhouryTA , AndersB , et al. Efficacy of once‐daily extended‐release topiramate (USL255): a subgroup analysis based on the level of treatment resistance. Epilepsy &amp; Behavior2014;41:136‐9. [PUBMED: 25461205] LawsonB , ChungSS , ClarkAM , HalvorsenMB , BlattI . Time to onset of efficacy and sustained treatment effects of USL255: results from the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):104, Abstract no: 1.222. NagaraddiV , ChungS , ArnoldS , ClarkA , AndersB , FakhouryT . Early onset of efficacy and safety outcomes with USL255 treatment: The PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.264. ">Chung 2014</a>; <a href="./references#CD001417-bbs2-0003" title="EltermanRD , GlauserTA , WyllieE , ReifeR , WuSC , PledgerG , et al. A double‐blind, randomized trial of topiramate as adjunctive therapy for partial‐onset seizures in children. Neurology1999;52(7):1338‐44. [PUBMED: 10227615] ">Elterman 1999</a>; <a href="./references#CD001417-bbs2-0004" title="FaughtE , WilderBJ , RamsayRE . Topiramate dose‐ranging trial in refractory partial epilepsy. Epilepsia1995;36(Suppl 4):33, Abstract no: D.9. FaughtE , WilderBJ , RamsayRE , ReifeRA , KramerLD , PledgerGW , et al. Topiramate placebo‐controlled dose‐ranging trial in refractory partial epilepsy using 200‐, 400‐, and 600‐mg daily dosages. Neurology1996;46(6):1684‐90. [PUBMED: 8649570] ">Faught 1996</a>; <a href="./references#CD001417-bbs2-0005" title="GubermanA , NetoW , Gassmann‐MayerC , EPAJ‐119 Study Group. Low‐dose topiramate in adults with treatment‐resistant partial‐onset seizures. Acta Neurologica Scandinavica2002;106(4):183‐9. [PUBMED: 12225311] GubermanA , NetoW , Gassmann‐MayerC , Topiramate EPAJ‐119 Study Group. Efficacy of 200 mg/day topiramate in treatment‐resistant partial seizures when added to an enzyme‐inducing anti‐epileptic drug (AED). Epilepsia2001;42(Suppl 7):179‐80, Abstract no: 2.244. NetoW , Gassmann‐MayerC , Topiramate EPAJ‐119 study group. Efficacy and tolerability of 200 mg/day topiramate in a placebo‐controlled comparison of titration rates. Epilepsia2000;41:35. VanOeneJ , NetoW , NilssonJ , HamiltonG , BaetenB , SchreinerA , et al. Weight reduction during topiramate treatment of partial seizures. Epilepsia2002;43(Suppl 8):152, Abstract no: P482. ">Guberman 2002</a>; <a href="./references#CD001417-bbs2-0006" title="Korean Topiramate Study Group. Topiramate in medically intractable partial epilepsies: double‐blind placebo‐controlled randomized parallel group trial. Epilepsia1999;40(12):1767‐74. [PUBMED: 10612342] LeeBI . Double‐blind placebo‐controlled randomized clinical trial of topiramate add‐on therapy in medically intractable partial epilepsies. Journal of the Korean Neurology Association1998;16(6):809‐19. ">Korean Topiramate Study Group 1999</a>; <a href="./references#CD001417-bbs2-0007" title="PriviteraM , FinchamR , PenryJ , ReifeR , KramerL , PledgerG , et al. Topiramate placebo‐controlled dose‐ranging trial in refractory partial epilepsy using 600‐, 800‐, and 1,000‐mg daily dosages. Neurology1996;46(6):1678‐83. [PUBMED: 8649569] PriviteraM , FinchamR , PenryJK . Dose‐ranging trial with higher doses of topiramate in patients with resistant partial seizures. Epilepsia1995;36(Suppl 4):33, Abstract no: D.7. ">Privitera 1996</a>; <a href="./references#CD001417-bbs2-0008" title="RosenfeldW , Abou‐KhalilB , ReifeR , HegadusR , PledgerG , Topiramate YF/YG Study Group. Placebo‐controlled trial of topiramate as adjunctive therapy to carbamazepine or phenytoin for partial‐onset seizures. Epilepsia1996;37(Suppl 5):153, Abstract no: 6.7. ">Rosenfeld 1996</a>; <a href="./references#CD001417-bbs2-0010" title="TassinariC , ChauvelP , ChodkiewiczJ , ShorvonSD , HenriksenO , DamM , et al. Double‐blind, placebo‐controlled trial of 600 mg/day topiramate as add‐on therapy in patients with refractory partial epilepsy. Epilepsia1995;36(Suppl 3):S150. TassinariCA , MichelucciR , ChauvelP , ChodkiewiczJ , ShorvonS , HenriksenO , et al. Double‐blind, placebo‐controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia1996;37(8):763‐8. [PUBMED: 8764816] ">Tassinari 1996</a>; <a href="./references#CD001417-bbs2-0012" title="ZhangL , HuangJ , ZhuangJH , HuangLQ , ZhaoZX . Topiramate as an adjunctive treatment for refractory partial epilepsy in the elderly. Journal of International Medical Research2011;39(2):408‐15. [PUBMED: 21672344] ">Zhang 2011</a>) and, therefore, we rated these studies as having unclear detection bias. We rated the other two studies at low risk of bias for this particular domain (<a href="./references#CD001417-bbs2-0009" title="ShariefM , ViteriC , Ben‐MenachemE , WeberM , ReifeR , PledgerG , et al. Double‐blind, placebo‐controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Research1996;25(3):217‐24. [PUBMED: 8956919] ShariefMK , SanderJW , PatsalosPN , ShorvonSD . Adjuvant topiramate treatment in intractable partial epilepsy. Epilepsia1993;6:41. ">Sharief 1996</a>; <a href="./references#CD001417-bbs2-0011" title="YenDJ , YuHY , GuoYC , ChenC , YiuCH , SuMS . A double‐blind, placebo‐controlled study of topiramate in adult patients with refractory partial epilepsy. Epilepsia2000;41(9):1162‐6. [PUBMED: 10999555] ">Yen 2000</a>), as the two studies specified that outcome assessors remained blinded. </p> </section> <section id="CD001417-sec-0077"> <h4 class="title">Incomplete outcome data</h4> <p>We rated all studies at low risk of bias for this domain due to the ITT analyses undertaken by the study authors. </p> </section> <section id="CD001417-sec-0078"> <h4 class="title">Selective reporting</h4> <p>We requested the protocols for all included studies to compare a priori methods and outcomes to the published report but the majority of these were unavailable. We rated all included studies as low risk of bias for this domain as there was no suspicion of selective outcome reporting bias; all expected outcomes were reported in each of the publications. </p> </section> <section id="CD001417-sec-0079"> <h4 class="title">Other potential sources of bias</h4> <p>We rated all studies at low risk of bias for this domain as we did not detect any further bias in any of the included studies. </p> </section> </section> <section id="CD001417-sec-0080"> <h3 class="title" id="CD001417-sec-0080">Effects of interventions</h3> <p>See: <a href="./full#CD001417-tbl-0001"><b>Summary of findings for the main comparison</b> Topiramate compared to placebo for drug‐resistant focal epilepsy</a> </p> <p>See <a href="./full#CD001417-tbl-0001">summary of findings Table for the main comparison</a> for a summary and GRADE assessment of the primary and secondary outcomes. </p> <section id="CD001417-sec-0081"> <h4 class="title">50% or greater reduction in seizure frequency</h4> <section id="CD001417-sec-0082"> <h5 class="title">Intention‐to‐treat (ITT) analysis</h5> <p>Data from all 12 studies and including 1650 participants contributed to this outcome. A Chi<sup>2</sup> test for heterogeneity in a response to topiramate showed significant heterogeneity between trials (Chi² = 18.29, df = 11, P = 0.07, I² = 40%), therefore we employed a random‐effects model. The overall risk ratio (RR) for a response to topiramate compared to placebo using the random‐effects model was 2.71 (95% confidence interval (CI) 2.05 to 3.59; 12 studies, 1650 participants; high‐certainty evidence; <a href="./references#CD001417-fig-0007" title="">Analysis 1.2</a>), indicating that participants receiving add‐on topiramate were nearly three times more likely to have a 50% or greater reduction in seizure frequency than those receiving add‐on placebo. </p> <p>As a result of the significant heterogeneity detected, we conducted three separate sensitivity analyses. Firstly, we noted that the studies included in the analysis for this outcome varied with regards to the overall risk of bias awarded. We thus completed a sensitivity analysis by study quality by only including studies associated with low risk of bias overall. Following this sensitivity analysis, the RR increased to 4.36 (95% CI 2.24 to 8.50) and there was no longer any detectable statistical heterogeneity (Chi² = 0.13, df = 2, P = 0.94, I² = 0%; <a href="./references#CD001417-fig-0006" title="">Analysis 1.1</a>). We similarly conducted a sensitivity analysis according to patient characteristics. For this, we excluded one study from the analysis because it studied a paediatric study population and all other studies were conducted in adults (<a href="./references#CD001417-bbs2-0003" title="EltermanRD , GlauserTA , WyllieE , ReifeR , WuSC , PledgerG , et al. A double‐blind, randomized trial of topiramate as adjunctive therapy for partial‐onset seizures in children. Neurology1999;52(7):1338‐44. [PUBMED: 10227615] ">Elterman 1999</a>). The exclusion of this study did not resolve the detected heterogeneity (Chi² = 17.94, df = 10, P = 0.06, I² = 44%) and did not greatly impact the estimated RR (RR 2.85, 95% CI 2.09 to 3.88; <a href="./references#CD001417-fig-0008" title="">Analysis 1.3</a>). Finally, we conducted a sensitivity analysis according to intervention, during which we excluded three studies (<a href="./references#CD001417-bbs2-0002" title="ArnoldS , BlattI , ClarkAM , HalvorsenMB , NagaraddiVN . USL255, a once‐daily, extended‐release topiramate, has positive effects on clinical outcomes and quality of life: results from the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):105, Abstract no: 1.223. BlattI , ChungSS , HoganRE , ClarkA , AndersB , HalvorsenM . Efficacy and safety of USL255, once‐daily extended‐release topiramate, in adults with partial onset seizures: the PREVAIL study. Epilepsia2014;55(Suppl 2):42‐43, Abstract no: p112. BlattI , NagaraddiV , HoganR , ArnoldS , LawsonB , AndersB , et al. Efficacy of USL255 across partial‐onset seizure types and refractory patient status: subgroup analyses from the PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.263. BlattI , NagaraddiVN , AndersB , ClarkAM , HalvorsenMB , HoganRE . USL255 is efficacious across all partial‐onset seizure types and with a variety of concomitant antiepileptic drugs: Results from subgroup analyses of the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):204, Abstract no: 2.116. ChungS . USL255 extended‐release topiramate for the treatment of epilepsy. Expert Review of Neurotherapeutics2014;14(10):1127‐37. [PUBMED: 25220748] ChungSS . A review of the efficacy and safety of extended‐release topiramate in the adjunctive treatment for refractory partial‐onset seizures. Therapeutic Advances in Neurological Disorders2015;8(3):131‐6. [PUBMED: 25941540] ChungSS , FakhouryTA , HoganRE , NagaraddiVN , BlattI , LawsonB , et al. Once‐daily USL255 as adjunctive treatment of partial‐onset seizures: randomized phase III study. Epilepsia2014;55(7):1077‐87. [PUBMED: 24902983] ChungSS , HoganR , BlattI , LawsonPB , NguyenH , ClarkAM , et al. Long‐term safety and sustained efficacy of USL255 (topiramate extended‐release capsules) in patients with refractory partial‐onset seizures. Epilepsy &amp; Behavior2016;59:13‐20. [PUBMED: 27084978] ClarkAM , ChungSS , BlattI , AndersB , HalvorsenMB , HoganRE . Efficacy of USL255 (qudexyTM XR; Extended‐release topiramate) in patients with refractory partial‐onset seizures: PREVAIL and PREVAIL OLE. Epilepsy Currents2015;15(Suppl 1):142‐3, Abstract no: 1.307. HoganR , ArnoldS , FakhouryT , AndersB . Adverse event profile of USL255 in patients with refractory partial‐onset seizures: the PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.262. HoganRE , ArnoldS , FakhouryTA , AndersB , LaineD , ToddWM , et al. Safety and tolerability of USL255 in subjects with refractory partial‐onset seizures: results from the randomized, phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):103‐4, Abstract no: 1.219. HoganRE , BlattI , LawsonB , NagaraddiV , FakhouryTA , AndersB , et al. Efficacy of once‐daily extended‐release topiramate (USL255): a subgroup analysis based on the level of treatment resistance. Epilepsy &amp; Behavior2014;41:136‐9. [PUBMED: 25461205] LawsonB , ChungSS , ClarkAM , HalvorsenMB , BlattI . Time to onset of efficacy and sustained treatment effects of USL255: results from the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):104, Abstract no: 1.222. NagaraddiV , ChungS , ArnoldS , ClarkA , AndersB , FakhouryT . Early onset of efficacy and safety outcomes with USL255 treatment: The PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.264. ">Chung 2014</a>; <a href="./references#CD001417-bbs2-0005" title="GubermanA , NetoW , Gassmann‐MayerC , EPAJ‐119 Study Group. Low‐dose topiramate in adults with treatment‐resistant partial‐onset seizures. Acta Neurologica Scandinavica2002;106(4):183‐9. [PUBMED: 12225311] GubermanA , NetoW , Gassmann‐MayerC , Topiramate EPAJ‐119 Study Group. Efficacy of 200 mg/day topiramate in treatment‐resistant partial seizures when added to an enzyme‐inducing anti‐epileptic drug (AED). Epilepsia2001;42(Suppl 7):179‐80, Abstract no: 2.244. NetoW , Gassmann‐MayerC , Topiramate EPAJ‐119 study group. Efficacy and tolerability of 200 mg/day topiramate in a placebo‐controlled comparison of titration rates. Epilepsia2000;41:35. VanOeneJ , NetoW , NilssonJ , HamiltonG , BaetenB , SchreinerA , et al. Weight reduction during topiramate treatment of partial seizures. Epilepsia2002;43(Suppl 8):152, Abstract no: P482. ">Guberman 2002</a>; <a href="./references#CD001417-bbs2-0012" title="ZhangL , HuangJ , ZhuangJH , HuangLQ , ZhaoZX . Topiramate as an adjunctive treatment for refractory partial epilepsy in the elderly. Journal of International Medical Research2011;39(2):408‐15. [PUBMED: 21672344] ">Zhang 2011</a>). The three excluded studies only assessed the lowest dosage of topiramate (200 mg/d). Again, heterogeneity was no longer detected amongst the data set (Chi² = 7.29, df = 8, P = 0.51, I² = 0%), however, the effect estimate remained statistically significant and was unsurprisingly slightly higher than that detected when all studies were included (RR 3.32, 95% CI 2.51 to 4.38; <a href="./references#CD001417-fig-0009" title="">Analysis 1.4</a>). We did not conduct a sensitivity analysis according to outcome as this was not deemed appropriate. </p> </section> <section id="CD001417-sec-0083"> <h5 class="title">Best‐ and worst‐case scenarios</h5> <p>We again used a random‐effects model for both the best‐case and worst‐case analyses due to the significant heterogeneity detected (Chi² = 20.93, df = 11, P = 0.03, I² = 47%; <a href="./references#CD001417-fig-0010" title="">Analysis 1.5</a>; and Chi² = 18.97, df = 11, P = 0.06, I² = 42%; <a href="./references#CD001417-fig-0011" title="">Analysis 1.6</a>, respectively). The overall best‐case RR scenario for a response to topiramate was RR 3.54 (95% CI 2.67 to 4.69), whilst the worst‐case RR scenario was 1.96 (95% CI 1.54 to 2.50). Importantly, all three analyses for the outcome, 50% or greater seizure reduction, suggest a significant treatment effect for add‐on topiramate compared to add‐on placebo (P &lt; 0.00001). </p> </section> <section id="CD001417-sec-0084"> <h5 class="title">Dose‐response regression</h5> <p>We fitted a generalised linear mixed model to the data provided in <a href="./references#CD001417-fig-0007" title="">Analysis 1.2</a> to estimate the effect of dose on the primary outcome, 50% or greater reduction in seizure frequency (details in <a href="#CD001417-sec-0063">Data synthesis</a>). To include the data extracted from the study by <a href="./references#CD001417-bbs2-0003" title="EltermanRD , GlauserTA , WyllieE , ReifeR , WuSC , PledgerG , et al. A double‐blind, randomized trial of topiramate as adjunctive therapy for partial‐onset seizures in children. Neurology1999;52(7):1338‐44. [PUBMED: 10227615] ">Elterman 1999</a>, which only recruited children, the daily dose was approximated by assuming an average adult weight of 75 kg, multiplied by the study dose of 6 mg/kg/day, to give 450 mg/day topiramate. It was not necessary to conduct any more dose adjustments for the other included studies. The study by <a href="./references#CD001417-bbs2-0012" title="ZhangL , HuangJ , ZhuangJH , HuangLQ , ZhaoZX . Topiramate as an adjunctive treatment for refractory partial epilepsy in the elderly. Journal of International Medical Research2011;39(2):408‐15. [PUBMED: 21672344] ">Zhang 2011</a> only recruited elderly patients, above 65 years of age, and the remaining studies all recruited patients from adult populations. Doses ranged between 200 mg/day and 1000 mg/day topiramate. In order to use this model, the dose was standardised by its standard deviation (352 mg). Importantly, the method used estimated an OR as opposed to a RR. </p> <p>The OR for a 50% or greater reduction in seizure frequency per 200 mg/d increase in topiramate dose was 1.45 (95% CI 1.28 to 1.64; P &lt; 0.001), with estimated between‐study standard deviation of 0.54 (standard error (SE) 0.16), thus revealing that patients were significantly more likely to attain a 50% or greater seizure reduction if their dose was increased by 200 mg/d (P &lt; 0.001). Notably, the odds of a patient achieving a 50% or greater reduction in seizure frequency were nearly doubled (OR 1.92, 95% CI 1.54 to 2.40; P &lt; 0.001) when their dose of topiramate was increased by 350 mg/d, the standard deviation of the included doses (P &lt; 0.001). </p> <p>The estimated response rate (the percentage of participants achieving a 50% or greater reduction in seizure frequency) per dose, as well as the estimated increase in response rate compared to placebo for each dose are given in <a href="#CD001417-tbl-0003">Table 2</a>. The estimated response rate on placebo was 17.8% (95% CI 6.3% to 29.4%), whereas the estimated response rate for topiramate ranged from 37.6% to 51.1%, dependent on dose (<a href="#CD001417-tbl-0003">Table 2</a>). Accordingly, the estimated response rate per dose compared to placebo ranged from 19.7% for participants randomised to 200 mg/day topiramate up to 33.3% for participants randomised to 1000 mg/day. Both the estimated fitted response rate and the difference in response rate compared to placebo generally increased with dosage, as would be expected from the dose‐response relationship demonstrated. </p> <div class="table" id="CD001417-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Estimated response rates per dose and percentage difference in responders per dose compared to placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Dose (mg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Fitted response rate (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Dose (mg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Difference in response<br/> rate from placebo (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>95% CI</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Lower</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Upper</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Lower</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Upper</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐28.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐46.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐12.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>450</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐16.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>450</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐35.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐6.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57.8</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence intervals</p> </div> </div> </section> </section> <section id="CD001417-sec-0085"> <h4 class="title">Seizure freedom</h4> <p>A Chi<sup>2</sup> test for heterogeneity showed no significant heterogeneity between trials (Chi² = 1.84, df = 6, P = 0.93, I² = 0%). The overall RR for seizure freedom was 3.67 (95% CI 1.79 to 7.54; 8 studies, 1177 participants; moderate‐certainty evidence; <a href="./references#CD001417-fig-0012" title="">Analysis 1.7</a>), indicating that participants randomised to add‐on topiramate were over three times more likely to attain seizure freedom than participants randomised to add‐on placebo. </p> </section> <section id="CD001417-sec-0086"> <h4 class="title">Treatment withdrawal</h4> <p>Data from 12 studies, consisting of 1650 participants, contributed to this outcome. A Chi<sup>2</sup> test for heterogeneity demonstrated no significant statistical heterogeneity (Chi² = 8.76, df = 10, P = 0.55, I² = 0%). The overall RR (95% CI) for withdrawal for any reason was 2.37 (95% CI 1.66 to 3.37; 12 studies, 1650 participants; high‐certainty evidence; <a href="./references#CD001417-fig-0013" title="">Analysis 1.8</a>), thus highlighting that participants were significantly more likely to withdraw from topiramate than placebo. </p> </section> <section id="CD001417-sec-0087"> <h4 class="title">Adverse effects</h4> <p>The RRs for adverse effects were as follows (<a href="./references#CD001417-fig-0014" title="">Analysis 1.9</a>). </p> <p> <ol id="CD001417-list-0012"> <li> <p>Ataxia: 2.29 (99% CI 1.10 to 4.77; 4 studies; 757 participants)</p> </li> <li> <p>Concentration difficulties: 7.81 (99% CI 2.08 to 29.29; 6 studies; 702 participants)</p> </li> <li> <p>Dizziness: 1.52 (99% CI 1.07 to 2.16; 8 studies; 1385 participants)</p> </li> <li> <p>Fatigue: 2.08 (99% CI 1.37 to 3.15; 9 studies; 1092 participants)</p> </li> <li> <p>Headache: 0.96 (99% CI 0.67 to 1.39; 10 studies; 1427 participants</p> </li> <li> <p>Nausea/vomiting: 1.50 (99% CI 0.71 to 3.15; 4 studies; 492 participants)</p> </li> <li> <p>Paraesthesia: 3.65 (99% CI 1.58 to 8.39; 7 studies; 1071 participants)</p> </li> <li> <p>Somnolence: 2.44 (99% CI 1.61 to 3.68; 9 studies; 1462 participants)</p> </li> <li> <p>Speech difficulty: 3.37 (99% CI 0.80 to 14.13; 3 studies; 310 participants)</p> </li> <li> <p>Thinking abnormally: 5.70 (99% CI 2.26 to 14.38; 4 studies; 640 participants)</p> </li> <li> <p>Weight loss/decrease: 3.99 (99% CI 1.82 to 8.72; 9 studies; 1070 participants)</p> </li> </ol> </p> <p>Collectively, the results imply that receiving add‐on topiramate is associated with a higher incidence rate for many adverse effects compared to add‐on placebo. Specifically, add‐on topiramate was associated with a significantly higher incidence rate for the following adverse effects: ataxia (P = 0.003), concentration difficulties (P &lt; 0.001), dizziness (P = 0.002), fatigue (P &lt; 0.001) , paraesthesia (P &lt; 0.001), somnolence (P &lt; 0.001), speech difficulty (P = 0.03), 'thinking abnormally' (P &lt; 0.001), and weight loss (P &lt; 0.001), although to differing degrees of effect. For example, the incidence rate for dizziness was increased by a modest 50% when receiving add‐on topiramate, whereas the incidence rate for 'thinking abnormally' was almost six times greater with add‐on topiramate than with placebo. Notably, however, add‐on topiramate did not incur a statistically significant increase in the risk of experiencing headache (RR 0.96, 99% CI 0.67 to 1.39; 9 studies; 1092 participants; P = 0.79) or nausea (RR 1.50, 99% CI 0.71 to 3.15; 4 studies; 492 participants; P = 0.16) compared to placebo. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001417-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001417-sec-0088"></div> <section id="CD001417-sec-0089"> <h3 class="title" id="CD001417-sec-0089">Summary of main results</h3> <p>The 12 trials included in this review were all double‐blinded and the majority expressly used adequate methods of allocation concealment. All analyses were by intention‐to‐treat (ITT). Results from the overall efficacy analysis show that topiramate is effective in reducing seizure frequency by at least 50% when used as an add‐on drug for people with drug‐resistant focal epilepsy. Topiramate was found to be almost three times more effective than a placebo drug. Even the lowest dose, 200 mg per day, results in nearly 20% more patients achieving a 50% reduction in seizure rate than placebo. The dose regression model shows increasing effect with increasing dose, though the increase is quite modest. For people taking 200 mg to 1000 mg per day, results indicate a response rate of between 38% (95% confidence interval (CI) 20.2 to 55.0) and 51% (95% CI 29.5 to 72.7), an improvement over placebo of 20% (CI ‐1.2 to 40.6) to 33% (CI 8.8 to 57.8). </p> <p>We suspected evidence of publication bias on examination of a funnel plot for the outcome, 50% or greater reduction in seizure frequency, plus we detected statistical heterogeneity in the data set. The heterogeneity could be explained by both study quality (excluding studies associated with unclear risk of bias) and by topiramate dosage. Specifically, statistical heterogeneity was no longer detected when studies which only investigated the lowest dosage of topiramate (200 mg) were excluded from the analysis. This generates further support for the observed dose‐response relationship as it suggests that lower dosage give a significantly different effect estimate compared to higher dosages, such that it generates methodological heterogeneity within the data set. </p> <p>For seizure freedom, the results estimate that topiramate is over three times more likely to be effective in stopping seizures completely, than a placebo drug. Only half of the included studies reported data on this outcome, however, and, as a result, this finding must be interpreted with caution. </p> <p>Results for the outcome, treatment withdrawal, showed that participants are significantly more likely to withdraw from treatment with add‐on topiramate than add‐on placebo. In trials of relatively short duration, such as those reviewed here, treatment withdrawal is likely to represent problems with tolerability rather than poor seizure control. With respect to adverse events, most of those investigated were significantly more likely to occur in the topiramate‐treated group, except for headache and nausea and vomiting. The risk ratio (RR) for the significant adverse effects ranged from a low of 1.52 for dizziness to a high of 7.81 for impaired concentration. Although many of the adverse effects were significantly more likely with add‐on topiramate, there was not sufficient information to determine whether this could be attributed to studies using higher doses. </p> </section> <section id="CD001417-sec-0090"> <h3 class="title" id="CD001417-sec-0090">Overall completeness and applicability of evidence</h3> <p>Primarily, this review aimed to determine the efficacy of topiramate as add‐on treatment for people of any age with drug‐resistant focal epilepsy. Markedly, however, the majority of the data were obtained from adults aged 16 to 65 years old. Only one study specifically evaluated the use of add‐on topiramate in children, aged 2 to 16 years (<a href="./references#CD001417-bbs2-0003" title="EltermanRD , GlauserTA , WyllieE , ReifeR , WuSC , PledgerG , et al. A double‐blind, randomized trial of topiramate as adjunctive therapy for partial‐onset seizures in children. Neurology1999;52(7):1338‐44. [PUBMED: 10227615] ">Elterman 1999</a>), and, equally, only one study investigated its use in the elderly (over 65 years old; <a href="./references#CD001417-bbs2-0012" title="ZhangL , HuangJ , ZhuangJH , HuangLQ , ZhaoZX . Topiramate as an adjunctive treatment for refractory partial epilepsy in the elderly. Journal of International Medical Research2011;39(2):408‐15. [PUBMED: 21672344] ">Zhang 2011</a>). Consequently, the findings presented here cannot be easily generalised to all age groups and are, instead, largely representative of the effect of add‐on topiramate in adults. </p> <p>Similarly, although the results of this review indicate that topiramate is likely an effective add‐on treatment with regard to seizure reduction, this review cannot tell us how topiramate compares with other antiepileptic drugs in this scenario. This is an extremely important issue for clinicians who are faced with an ever‐increasing number of antiepileptic drugs to choose from. Head‐to‐head trials are needed to provide the evidence that is necessary to enable clinicians to make an evidence‐based choice between antiepileptic drugs and their inclusion should be considered for future review updates. </p> <p>Moreover, with the possibility of publication bias, we cannot be completely certain that we have identified all placebo‐controlled trials evaluating add‐on topiramate. The suspected publication bias suggests that there could be several small studies, possibly with negative results, which have remained unpublished and that may not have been highlighted by our searches. This generates uncertainty in our finding that add‐on topiramate is more effective than placebo. The implications of this are addressed further in the subsequent subsections. </p> <p>Additionally, this review focuses on the use of topiramate in drug‐resistant focal epilepsy. The results cannot, therefore, be generalised to add‐on treatment for generalised epilepsies. Likewise, no inference can be made about the effects of topiramate when used as monotherapy. </p> <section id="CD001417-sec-0091"> <h4 class="title">Certainty of the evidence</h4> <p>Out of the 12 included studies, we rated all but three of the studies as having unclear risk of bias. We rated the other three studies as having low risk of bias. Taking all the studies together, we rated the overall risk of bias as low and considered the evidence to be methodologically sound. The most common issue to generate risk of bias was the blinding of outcome assessors. Nine of the included studies did not provide explicit details on the blinding of outcome assessors, however, given the self‐report aspect of the outcomes measured, i.e. seizure frequency and adverse effects experienced, the blinding of outcome assessors was deemed to have minimal impact on the effect size estimated, hence the overall assessment of low risk of bias. </p> <p>We employed the GRADE approach to rate the level of certainty of evidence per outcome, the results of which are presented in <a href="./full#CD001417-tbl-0001">summary of findings Table for the main comparison</a>. We did not downgrade any of the outcomes for risk of bias, as reasoned above. For the main outcome of 50% or greater seizure reduction, we rated the certainty of evidence as high. We downgraded the evidence for 50% or greater seizure reduction once due to the influence that publication bias may have had on the overall effect estimate. Specifically, a lack of symmetry was noted in the funnel plot for the primary outcome during visual examination (<a href="#CD001417-fig-0004">Figure 4</a>). This observation was then supported by the Egger test which detected significant publication bias within the meta‐analysis (P = 0.001). We downgraded the evidence once more due to inconsistency resulting from significant statistical heterogeneity detected within the data set. We then upgraded the evidence once for a large effect size (RR &gt; 2.00), and once again due to the dose‐response relationship demonstrated for the outcome. </p> <div class="figure" id="CD001417-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Topiramate versus placebo, outcome: 1.2 50% reduction in seizure frequency ‐ ITT analysis." data-id="CD001417-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Topiramate versus placebo, outcome: 1.2 50% reduction in seizure frequency ‐ ITT analysis. </p> </div> </div> </div> <p>We judged the evidence for the alternative efficacy outcome, seizure freedom, to be of moderate certainty. We downgraded the evidence twice due to the very low number of events contributing to the meta‐analysis, but then upgraded once because of the large effect size (RR &gt; 2.00) observed. Similarly, we downgraded the certainty of evidence for the adverse effects: weight loss, paraesthesia, and difficulties with concentration, twice because these outcomes, likewise, featured an extremely low number of events (&lt; 100 events). For the outcome, weight loss, we downgraded the evidence once again as a result of suspected publication bias (Egger test: P = 0.009). We then upgraded the evidence for weight loss once due to the large effect size observed, thus producing an overall judgement of low‐certainty of evidence for this outcome. We downgraded the evidence for the outcome, concentration difficulties, once for suspected publication bias (Egger test: P = 0.019) but then upgraded this twice due to the very large effect size recognised (RR &gt; 5.00). This led to an overall judgement of moderate‐certainty of evidence for concentration difficulties. We also judged the evidence for paraesthesia as being of moderate certainty. We did not detect any publication bias in the data set (Egger test: P = 0.478), however, we could only upgrade the evidence once back to moderate certainty as the observed effect size was large, as opposed to very large. </p> <p>In contrast, we only downgraded the evidence for the other two outcomes, treatment withdrawal and abnormal thinking, once for imprecision. Although the number of events was insufficient to satisfy the optimal information size, there were more events than were noted for the other outcomes (&gt; 100 events). We then upgraded the evidence for both outcomes back to high certainty due to the large (treatment withdrawal) and very large (abnormal thinking) effect size revealed. </p> </section> </section> <section id="CD001417-sec-0092"> <h3 class="title" id="CD001417-sec-0092">Potential biases in the review process</h3> <p>We strongly suspect that publication bias has impacted this review. We specifically suspect publication bias for three of the GRADE‐assessed outcomes (50% or greater seizure reduction, concentration difficulties, and weight loss) after examining the resultant funnel plots and conducting the Egger test. Importantly, publication bias was also suspected for the outcome, seizure freedom, however, the low number of studies contributing data for this outcome prevented us from making a conclusive judgement regarding the funnel plot (<a href="#CD001417-fig-0005">Figure 5</a>), and this was reflected in the results of the Egger test (P = 0.09). </p> <div class="figure" id="CD001417-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Topiramate versus placebo, outcome: 1.7 Seizure freedom." data-id="CD001417-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Topiramate versus placebo, outcome: 1.7 Seizure freedom.</p> </div> </div> </div> <p>Studies showing positive results are more likely to be published than those expressing negative results and this consequently leads to an overestimation of the effect size (<a href="./references#CD001417-bbs2-0031" title="MuradMH , ChuH , LinL , WangZ . The effect of publication bias magnitude and direction on the certainty in evidence. BMJ Evidence‐Based Medicine2018;23(3):84‐6. [DOI: 10.1136/bmjebm‐2018‐110891; PUBMED: 29650725] ">Murad 2018</a>). It is thus possible that, in the instance of this particular review, we have overestimated the effectiveness of topiramate compared to placebo as an add‐on therapy. Expanding the search terms in future updates could aid us in identifying any additional unpublished data sets to help resolve this issue. Additionally, we could contact more individuals that might have knowledge of any unpublished trials. We do, however, feel that, for the purposes of this current review update, we have exhausted all potential sources of data. This will, however, be reassessed and further pursued for the next review update. </p> </section> <section id="CD001417-sec-0093"> <h3 class="title" id="CD001417-sec-0093">Agreements and disagreements with other studies or reviews</h3> <p>The observations made in this review update are consistent with the previous versions of this review (<a href="./references#CD001417-bbs2-0042" title="JetteNJ , MarsonAG , HuttonJL . Topiramate add‐on for drug‐resistant partial epilepsy. Cochrane Database of Systematic Reviews2002, Issue 3. [DOI: 10.1002/14651858.CD001417] ">Jette 2002</a>; <a href="./references#CD001417-bbs2-0043" title="JetteN , HemmingK , HuttonJ , MarsonA . Topiramate add‐on for drug‐resistant partial epilepsy. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD001417.pub2] ">Jette 2008</a>; <a href="./references#CD001417-bbs2-0044" title="MarsonAG , KadirZA , ChadwickDW . New antiepileptic drugs; a systematic review of their efficacy and tolerability. BMJ1996;313:1169‐74. ">Marson 1996</a>; <a href="./references#CD001417-bbs2-0045" title="MarsonAG , KadirZA , HuttonJL , ChadwickDW . The new antiepileptic drugs; a systematic review of their efficacy and tolerability. Epilepsia1997;38:859‐80. ">Marson 1997</a>; <a href="./references#CD001417-bbs2-0046" title="PulmanJ , JetteN , DykemanJ , HemmingK , HuttonJL , MarsonAG . Topiramate add‐on for drug‐resistant partial epilepsy. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD001417.pub3] ">Pulman 2014</a>). Specifically, this review has indicated that topiramate is efficacious as an add‐on treatment for drug‐resistant focal epilepsy. This review has, however, also emphasised that treatment with topiramate remains significantly associated with certain adverse effects, including: concentration difficulties, paraesthesia, 'thinking abnormally', and weight loss. As with the earlier versions of this review, we are still unable to extrapolate the results to other types of epilepsy and cannot comment on the long‐term effectiveness or tolerability of topiramate as an add‐on treatment. </p> <p>The results of this review are also consistent with other reviews (<a href="./references#CD001417-bbs2-0032" title="PeruccaE . A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacological Research1997;35(4):241‐56. [PUBMED: 9264038] ">Perucca 1997</a>; <a href="./references#CD001417-bbs2-0033" title="PriviteraMD . Topiramate: a new antiepileptic drug. The Annals of Pharmacotherapy1997;31(10):1164‐73. [PUBMED: 9337443] ">Privitera 1997</a>), conducted independently of Cochrane, however, these reviews are now outdated. Notably, <a href="./references#CD001417-bbs2-0032" title="PeruccaE . A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacological Research1997;35(4):241‐56. [PUBMED: 9264038] ">Perucca 1997</a> similarly reported that doses of topiramate between 200 mg/day to 1000 mg/day are effective at managing drug‐resistant focal epilepsy, emphasising that even doses below 400 mg/day are likely to be beneficial. The other review identified (<a href="./references#CD001417-bbs2-0033" title="PriviteraMD . Topiramate: a new antiepileptic drug. The Annals of Pharmacotherapy1997;31(10):1164‐73. [PUBMED: 9337443] ">Privitera 1997</a>), likewise noted a two‐ to three‐fold difference in the number of people achieving 50% reduction in seizure frequency when allocated add‐on topiramate compared to placebo. Both reviews also described ataxia, concentration difficulties, paraesthesias, fatigue, dizziness, somnolence and weight loss in their participant‐reported adverse effects (<a href="./references#CD001417-bbs2-0032" title="PeruccaE . A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacological Research1997;35(4):241‐56. [PUBMED: 9264038] ">Perucca 1997</a>; <a href="./references#CD001417-bbs2-0033" title="PriviteraMD . Topiramate: a new antiepileptic drug. The Annals of Pharmacotherapy1997;31(10):1164‐73. [PUBMED: 9337443] ">Privitera 1997</a>). </p> <p>Of further significance, two of the trials included in this review explored dose‐response relationships (<a href="./references#CD001417-bbs2-0004" title="FaughtE , WilderBJ , RamsayRE . Topiramate dose‐ranging trial in refractory partial epilepsy. Epilepsia1995;36(Suppl 4):33, Abstract no: D.9. FaughtE , WilderBJ , RamsayRE , ReifeRA , KramerLD , PledgerGW , et al. Topiramate placebo‐controlled dose‐ranging trial in refractory partial epilepsy using 200‐, 400‐, and 600‐mg daily dosages. Neurology1996;46(6):1684‐90. [PUBMED: 8649570] ">Faught 1996</a>; <a href="./references#CD001417-bbs2-0007" title="PriviteraM , FinchamR , PenryJ , ReifeR , KramerL , PledgerG , et al. Topiramate placebo‐controlled dose‐ranging trial in refractory partial epilepsy using 600‐, 800‐, and 1,000‐mg daily dosages. Neurology1996;46(6):1678‐83. [PUBMED: 8649569] PriviteraM , FinchamR , PenryJK . Dose‐ranging trial with higher doses of topiramate in patients with resistant partial seizures. Epilepsia1995;36(Suppl 4):33, Abstract no: D.7. ">Privitera 1996</a>). <a href="./references#CD001417-bbs2-0004" title="FaughtE , WilderBJ , RamsayRE . Topiramate dose‐ranging trial in refractory partial epilepsy. Epilepsia1995;36(Suppl 4):33, Abstract no: D.9. FaughtE , WilderBJ , RamsayRE , ReifeRA , KramerLD , PledgerGW , et al. Topiramate placebo‐controlled dose‐ranging trial in refractory partial epilepsy using 200‐, 400‐, and 600‐mg daily dosages. Neurology1996;46(6):1684‐90. [PUBMED: 8649570] ">Faught 1996</a> considered responses at doses of 200 mg, 400 mg and 600 mg per day, whilst <a href="./references#CD001417-bbs2-0007" title="PriviteraM , FinchamR , PenryJ , ReifeR , KramerL , PledgerG , et al. Topiramate placebo‐controlled dose‐ranging trial in refractory partial epilepsy using 600‐, 800‐, and 1,000‐mg daily dosages. Neurology1996;46(6):1678‐83. [PUBMED: 8649569] PriviteraM , FinchamR , PenryJK . Dose‐ranging trial with higher doses of topiramate in patients with resistant partial seizures. Epilepsia1995;36(Suppl 4):33, Abstract no: D.7. ">Privitera 1996</a> evaluated responses at 600 mg, 800 mg and 1000 mg per day. Results from <a href="./references#CD001417-bbs2-0004" title="FaughtE , WilderBJ , RamsayRE . Topiramate dose‐ranging trial in refractory partial epilepsy. Epilepsia1995;36(Suppl 4):33, Abstract no: D.9. FaughtE , WilderBJ , RamsayRE , ReifeRA , KramerLD , PledgerGW , et al. Topiramate placebo‐controlled dose‐ranging trial in refractory partial epilepsy using 200‐, 400‐, and 600‐mg daily dosages. Neurology1996;46(6):1684‐90. [PUBMED: 8649570] ">Faught 1996</a> suggest that 400 mg/day topiramate increases the likelihood of a response compared to a 200 mg/day dose, but that no further increase is obtainable at doses of 600 mg/day. Results from <a href="./references#CD001417-bbs2-0007" title="PriviteraM , FinchamR , PenryJ , ReifeR , KramerL , PledgerG , et al. Topiramate placebo‐controlled dose‐ranging trial in refractory partial epilepsy using 600‐, 800‐, and 1,000‐mg daily dosages. Neurology1996;46(6):1678‐83. [PUBMED: 8649569] PriviteraM , FinchamR , PenryJK . Dose‐ranging trial with higher doses of topiramate in patients with resistant partial seizures. Epilepsia1995;36(Suppl 4):33, Abstract no: D.7. ">Privitera 1996</a> also suggest little difference in response rates between doses of 600 mg/day to 1000 mg/day. Although neither study observed an increased response rate with doses in excess of 600 mg/day, this current review successfully demonstrated a significant dose‐response relationship whilst including all doses from 200 mg/day to 1000 mg/day. Importantly, although the response rates were very similar for 600 mg/day and 800 mg/day, the response rate continued to increase again when participants were randomised to the highest dose, 1000 mg/day, contrary to the reports in these two studies. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001417-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/urn:x-wiley:14651858:media:CD001417:CD001417-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_t/tCD001417-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD001417-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/full#CD001417-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001417-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/urn:x-wiley:14651858:media:CD001417:CD001417-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_t/tCD001417-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001417-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/full#CD001417-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001417-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/urn:x-wiley:14651858:media:CD001417:CD001417-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_t/tCD001417-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001417-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/full#CD001417-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001417-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/urn:x-wiley:14651858:media:CD001417:CD001417-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_t/tCD001417-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Topiramate versus placebo, outcome: 1.2 50% reduction in seizure frequency ‐ ITT analysis." data-id="CD001417-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Topiramate versus placebo, outcome: 1.2 50% reduction in seizure frequency ‐ ITT analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/full#CD001417-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001417-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/urn:x-wiley:14651858:media:CD001417:CD001417-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_t/tCD001417-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Topiramate versus placebo, outcome: 1.7 Seizure freedom." data-id="CD001417-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Topiramate versus placebo, outcome: 1.7 Seizure freedom.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/full#CD001417-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001417-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/urn:x-wiley:14651858:media:CD001417:CD001417-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_t/tCD001417-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topiramate versus placebo, Outcome 1 50% reduction in seizure frequency ‐ Sensitivity analysis by study quality." data-id="CD001417-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Topiramate versus placebo, Outcome 1 50% reduction in seizure frequency ‐ Sensitivity analysis by study quality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/references#CD001417-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001417-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/urn:x-wiley:14651858:media:CD001417:CD001417-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_t/tCD001417-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topiramate versus placebo, Outcome 2 50% reduction in seizure frequency ‐ ITT analysis." data-id="CD001417-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Topiramate versus placebo, Outcome 2 50% reduction in seizure frequency ‐ ITT analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/references#CD001417-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001417-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/urn:x-wiley:14651858:media:CD001417:CD001417-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_t/tCD001417-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topiramate versus placebo, Outcome 3 50% reduction in seizure frequency ‐ Sensitivity analysis by patient characteristics (age)." data-id="CD001417-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Topiramate versus placebo, Outcome 3 50% reduction in seizure frequency ‐ Sensitivity analysis by patient characteristics (age). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/references#CD001417-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001417-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/urn:x-wiley:14651858:media:CD001417:CD001417-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_t/tCD001417-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topiramate versus placebo, Outcome 4 50% reduction in seizure frequency ‐ Sensitivity analysis by intervention (dosage)." data-id="CD001417-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Topiramate versus placebo, Outcome 4 50% reduction in seizure frequency ‐ Sensitivity analysis by intervention (dosage). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/references#CD001417-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001417-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/urn:x-wiley:14651858:media:CD001417:CD001417-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_t/tCD001417-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topiramate versus placebo, Outcome 5 50% reduction in seizure frequency ‐ Best‐case analysis." data-id="CD001417-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Topiramate versus placebo, Outcome 5 50% reduction in seizure frequency ‐ Best‐case analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/references#CD001417-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001417-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/urn:x-wiley:14651858:media:CD001417:CD001417-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_t/tCD001417-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topiramate versus placebo, Outcome 6 50% reduction in seizure frequency ‐ Worst‐case analysis." data-id="CD001417-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Topiramate versus placebo, Outcome 6 50% reduction in seizure frequency ‐ Worst‐case analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/references#CD001417-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001417-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/urn:x-wiley:14651858:media:CD001417:CD001417-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_t/tCD001417-CMP-001-07.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topiramate versus placebo, Outcome 7 Seizure freedom." data-id="CD001417-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Topiramate versus placebo, Outcome 7 Seizure freedom.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/references#CD001417-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001417-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/urn:x-wiley:14651858:media:CD001417:CD001417-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_t/tCD001417-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topiramate versus placebo, Outcome 8 Treatment withdrawal." data-id="CD001417-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Topiramate versus placebo, Outcome 8 Treatment withdrawal.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/references#CD001417-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001417-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/urn:x-wiley:14651858:media:CD001417:CD001417-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_t/tCD001417-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topiramate versus placebo, Outcome 9 Adverse effects." data-id="CD001417-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Topiramate versus placebo, Outcome 9 Adverse effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/references#CD001417-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/media/CDSR/CD001417/image_n/nCD001417-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001417-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Topiramate compared to placebo for drug‐resistant focal epilepsy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Add‐on topiramate compared to placebo for drug‐resistant focal epilepsy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patients or population:</b> people with drug‐resistant focal epilepsy<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> add‐on topiramate<br/> <b>Comparison:</b> add‐on placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI; Adverse effects: 99% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with topiramate</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>50% or greater reduction in seizure frequency (ITT analysis)</b> </p> <p>Follow‐up: range 11 to 19 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.71</b><br/> (2.05 to 3.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>1650</b><br/> (12 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b><sup>a,b,c,f,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Topiramate increases the proportion of participants attaining a 50% or greater reduction in seizure frequency. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>163 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>441 per 1000<br/> (333 to 584) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Seizure freedom</b> </p> <p>Follow‐up: range 11 to 19 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 3.67</b><br/> (1.79 to 7.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1177<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Topiramate likely increases the proportion of participants achieving seizure freedom.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1000<br/> (30 to 125) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment withdrawal</b> </p> <p>Follow‐up: range 11 to 19 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.37</b><br/> (1.66 to 3.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>1650</b><br/> (12 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b><sup>a,d,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Topiramate increases the incidence of treatment withdrawal.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>144 per 1000<br/> (101 to 204) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects ‐ weight loss/decrease</b> </p> <p>Follow‐up: range 11 to 18 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 3.99</b><br/> (1.82 to 8.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>1070</b><br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c,e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Topiramate may produce a large increase in the proportion of participants experiencing weight loss. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81 per 1000<br/> (37 to 177) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects ‐ paraesthesia</b> </p> <p>Follow‐up: range 11 to 18 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 3.65</b><br/> (1.58 to 8.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>1071</b><br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Topiramate likely increases the proportion of participants experiencing paraesthesia.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>91 per 1000<br/> (40 to 210) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects ‐ 'thinking abnormally'</b> </p> <p>Follow‐up: range 12 to 19 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 5.70</b><br/> (2.26 to 14.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>640</b><br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b><sup>a,d,g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Topiramate increases the proportion of participants reporting that they are 'thinking abnormally'. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>243 per 1000<br/> (96 to 614) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects ‐ difficulty with concentration/concentration impaired/concentration‐attention difficulties</b> </p> <p>Follow‐up: range 11 to 18 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 7.81</b><br/> (2.08 to 29.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>702</b><br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,c,e,g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Topiramate likely increases the number of participants who experience difficulty with concentration. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88 per 1000<br/> (23 to 330) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% or 99% confidence interval, dependent on the outcome) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% or 99% CI, dependent on the outcome).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We did not downgrade evidence for risk of bias; we judged risk of bias across studies to be low. Ten studies did not describe the blinding of outcome assessors, one study failed to explain randomisation and allocation concealment and another did not describe any method of blinding. We, however, reasoned that the blinding of outcome assessors would minimally impact the estimated effect size due to the self‐reported nature of the review outcomes.<br/> <sup>b</sup>We downgraded the evidence once for inconsistency: we detected significant statistical heterogeneity.<br/> <sup>c</sup>We downgraded the evidence once for publication bias: examination of funnel plot and Egger test indicates the possibility of publication bias.<br/> <sup>d</sup>We downgraded the evidence once for imprecision: the number of events (&lt; 400) did not suffice optimal information size.<br/> <sup>e</sup>We downgraded the evidence twice for imprecision: the number of events (&lt; 100) did not suffice optimal information size.<br/> <sup>f</sup>We upgraded the evidence once for large effect: RR &gt; 2.00.<br/> <sup>g</sup>We upgraded the evidence twice for large effect: RR &gt; 5.00.<br/> <sup>h</sup>We upgraded the evidence once for dose‐response gradient: logistic regression demonstrated a significant dose‐response relationship. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Topiramate compared to placebo for drug‐resistant focal epilepsy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/full#CD001417-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001417-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study characteristics</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study name</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of previous AEDs</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline period</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment period</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001417-bbs2-0001" title="Ben‐MenachemE , DamM , HenriksenO , SchmidtD . Double‐blind, placebo‐controlled trial of 800 mg/day topiramate as add‐on therapy in patients with refractory partial epilepsy. Epilepsia1995;36(Suppl 3):S150. Ben‐MenachemE , DamM , MikkelsenM , EngelskjonT , HenriksenO , JohannessenS , et al. Topiramate add‐on treatment in patients with intractable partial epilepsy: a multicenter study. Epilepsia1993;34(Suppl 2):109. Ben‐MenachemE , HenriksenO , DamM , MikkelsenM , SchmidtD , ReidS , et al. Double‐blind, placebo‐controlled trial of topiramate as add‐on therapy in patients with refractory partial seizures. Epilepsia1996;37(6):539‐43. [PUBMED: 8641230] Martinez‐LageJ , Ben‐MenachemE , ShorvonSD , WeberM . Double‐blind, placebo‐controlled trial of 400 mg/day topiramate as add‐on therapy in patients with refractory partial epilepsy. Epilepsia1995;36(Suppl 3):S149‐50. OstergardL , DamM , MikkelsenM . Topiramate as add‐on therapy in refractory partial epilepsy. Epilepsia1992;33(Suppl 3):105. ">Ben‐Menachem 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sweden, Norway, Denmark, Germany</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001417-bbs2-0002" title="ArnoldS , BlattI , ClarkAM , HalvorsenMB , NagaraddiVN . USL255, a once‐daily, extended‐release topiramate, has positive effects on clinical outcomes and quality of life: results from the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):105, Abstract no: 1.223. BlattI , ChungSS , HoganRE , ClarkA , AndersB , HalvorsenM . Efficacy and safety of USL255, once‐daily extended‐release topiramate, in adults with partial onset seizures: the PREVAIL study. Epilepsia2014;55(Suppl 2):42‐43, Abstract no: p112. BlattI , NagaraddiV , HoganR , ArnoldS , LawsonB , AndersB , et al. Efficacy of USL255 across partial‐onset seizure types and refractory patient status: subgroup analyses from the PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.263. BlattI , NagaraddiVN , AndersB , ClarkAM , HalvorsenMB , HoganRE . USL255 is efficacious across all partial‐onset seizure types and with a variety of concomitant antiepileptic drugs: Results from subgroup analyses of the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):204, Abstract no: 2.116. ChungS . USL255 extended‐release topiramate for the treatment of epilepsy. Expert Review of Neurotherapeutics2014;14(10):1127‐37. [PUBMED: 25220748] ChungSS . A review of the efficacy and safety of extended‐release topiramate in the adjunctive treatment for refractory partial‐onset seizures. Therapeutic Advances in Neurological Disorders2015;8(3):131‐6. [PUBMED: 25941540] ChungSS , FakhouryTA , HoganRE , NagaraddiVN , BlattI , LawsonB , et al. Once‐daily USL255 as adjunctive treatment of partial‐onset seizures: randomized phase III study. Epilepsia2014;55(7):1077‐87. [PUBMED: 24902983] ChungSS , HoganR , BlattI , LawsonPB , NguyenH , ClarkAM , et al. Long‐term safety and sustained efficacy of USL255 (topiramate extended‐release capsules) in patients with refractory partial‐onset seizures. Epilepsy &amp; Behavior2016;59:13‐20. [PUBMED: 27084978] ClarkAM , ChungSS , BlattI , AndersB , HalvorsenMB , HoganRE . Efficacy of USL255 (qudexyTM XR; Extended‐release topiramate) in patients with refractory partial‐onset seizures: PREVAIL and PREVAIL OLE. Epilepsy Currents2015;15(Suppl 1):142‐3, Abstract no: 1.307. HoganR , ArnoldS , FakhouryT , AndersB . Adverse event profile of USL255 in patients with refractory partial‐onset seizures: the PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.262. HoganRE , ArnoldS , FakhouryTA , AndersB , LaineD , ToddWM , et al. Safety and tolerability of USL255 in subjects with refractory partial‐onset seizures: results from the randomized, phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):103‐4, Abstract no: 1.219. HoganRE , BlattI , LawsonB , NagaraddiV , FakhouryTA , AndersB , et al. Efficacy of once‐daily extended‐release topiramate (USL255): a subgroup analysis based on the level of treatment resistance. Epilepsy &amp; Behavior2014;41:136‐9. [PUBMED: 25461205] LawsonB , ChungSS , ClarkAM , HalvorsenMB , BlattI . Time to onset of efficacy and sustained treatment effects of USL255: results from the phase 3 PREVAIL clinical trial. Epilepsy Currents2014;14(Suppl 1):104, Abstract no: 1.222. NagaraddiV , ChungS , ArnoldS , ClarkA , AndersB , FakhouryT . Early onset of efficacy and safety outcomes with USL255 treatment: The PREVAIL study. Neurology2014;82(10 Suppl):Abstract no: P3.264. ">Chung 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Argentina, Australia, Belgium, Canada, Chile, Germany, Greece, Hungary, India, Israel, New Zealand, Poland, Russia, South Africa, Spain, USA </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 to ≥7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001417-bbs2-0003" title="EltermanRD , GlauserTA , WyllieE , ReifeR , WuSC , PledgerG , et al. A double‐blind, randomized trial of topiramate as adjunctive therapy for partial‐onset seizures in children. Neurology1999;52(7):1338‐44. [PUBMED: 10227615] ">Elterman 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA, Costa Rica</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001417-bbs2-0004" title="FaughtE , WilderBJ , RamsayRE . Topiramate dose‐ranging trial in refractory partial epilepsy. Epilepsia1995;36(Suppl 4):33, Abstract no: D.9. FaughtE , WilderBJ , RamsayRE , ReifeRA , KramerLD , PledgerGW , et al. Topiramate placebo‐controlled dose‐ranging trial in refractory partial epilepsy using 200‐, 400‐, and 600‐mg daily dosages. Neurology1996;46(6):1684‐90. [PUBMED: 8649570] ">Faught 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>181</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001417-bbs2-0005" title="GubermanA , NetoW , Gassmann‐MayerC , EPAJ‐119 Study Group. Low‐dose topiramate in adults with treatment‐resistant partial‐onset seizures. Acta Neurologica Scandinavica2002;106(4):183‐9. [PUBMED: 12225311] GubermanA , NetoW , Gassmann‐MayerC , Topiramate EPAJ‐119 Study Group. Efficacy of 200 mg/day topiramate in treatment‐resistant partial seizures when added to an enzyme‐inducing anti‐epileptic drug (AED). Epilepsia2001;42(Suppl 7):179‐80, Abstract no: 2.244. NetoW , Gassmann‐MayerC , Topiramate EPAJ‐119 study group. Efficacy and tolerability of 200 mg/day topiramate in a placebo‐controlled comparison of titration rates. Epilepsia2000;41:35. VanOeneJ , NetoW , NilssonJ , HamiltonG , BaetenB , SchreinerA , et al. Weight reduction during topiramate treatment of partial seizures. Epilepsia2002;43(Suppl 8):152, Abstract no: P482. ">Guberman 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hungary, Poland, Israel, Canada, Russia, Czech Republic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>263</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001417-bbs2-0006" title="Korean Topiramate Study Group. Topiramate in medically intractable partial epilepsies: double‐blind placebo‐controlled randomized parallel group trial. Epilepsia1999;40(12):1767‐74. [PUBMED: 10612342] LeeBI . Double‐blind placebo‐controlled randomized clinical trial of topiramate add‐on therapy in medically intractable partial epilepsies. Journal of the Korean Neurology Association1998;16(6):809‐19. ">Korean Topiramate Study Group 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Korea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>177</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001417-bbs2-0007" title="PriviteraM , FinchamR , PenryJ , ReifeR , KramerL , PledgerG , et al. Topiramate placebo‐controlled dose‐ranging trial in refractory partial epilepsy using 600‐, 800‐, and 1,000‐mg daily dosages. Neurology1996;46(6):1678‐83. [PUBMED: 8649569] PriviteraM , FinchamR , PenryJK . Dose‐ranging trial with higher doses of topiramate in patients with resistant partial seizures. Epilepsia1995;36(Suppl 4):33, Abstract no: D.7. ">Privitera 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>190</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001417-bbs2-0008" title="RosenfeldW , Abou‐KhalilB , ReifeR , HegadusR , PledgerG , Topiramate YF/YG Study Group. Placebo‐controlled trial of topiramate as adjunctive therapy to carbamazepine or phenytoin for partial‐onset seizures. Epilepsia1996;37(Suppl 5):153, Abstract no: 6.7. ">Rosenfeld 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>209</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001417-bbs2-0009" title="ShariefM , ViteriC , Ben‐MenachemE , WeberM , ReifeR , PledgerG , et al. Double‐blind, placebo‐controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Research1996;25(3):217‐24. [PUBMED: 8956919] ShariefMK , SanderJW , PatsalosPN , ShorvonSD . Adjuvant topiramate treatment in intractable partial epilepsy. Epilepsia1993;6:41. ">Sharief 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sweden, Spain, UK, France</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001417-bbs2-0010" title="TassinariC , ChauvelP , ChodkiewiczJ , ShorvonSD , HenriksenO , DamM , et al. Double‐blind, placebo‐controlled trial of 600 mg/day topiramate as add‐on therapy in patients with refractory partial epilepsy. Epilepsia1995;36(Suppl 3):S150. TassinariCA , MichelucciR , ChauvelP , ChodkiewiczJ , ShorvonS , HenriksenO , et al. Double‐blind, placebo‐controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia1996;37(8):763‐8. [PUBMED: 8764816] ">Tassinari 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK, Italy, France, Norway, Denmark</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001417-bbs2-0011" title="YenDJ , YuHY , GuoYC , ChenC , YiuCH , SuMS . A double‐blind, placebo‐controlled study of topiramate in adult patients with refractory partial epilepsy. Epilepsia2000;41(9):1162‐6. [PUBMED: 10999555] ">Yen 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001417-bbs2-0012" title="ZhangL , HuangJ , ZhuangJH , HuangLQ , ZhaoZX . Topiramate as an adjunctive treatment for refractory partial epilepsy in the elderly. Journal of International Medical Research2011;39(2):408‐15. [PUBMED: 21672344] ">Zhang 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Elderly</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>AED: antiepileptic drug</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/full#CD001417-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001417-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Estimated response rates per dose and percentage difference in responders per dose compared to placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Dose (mg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Fitted response rate (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Dose (mg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Difference in response<br/> rate from placebo (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>95% CI</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Lower</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Upper</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Lower</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Upper</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐28.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐46.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐12.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>450</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐16.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>450</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐35.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐6.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57.8</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>CI: confidence intervals</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Estimated response rates per dose and percentage difference in responders per dose compared to placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/full#CD001417-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001417-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Topiramate versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 50% reduction in seizure frequency ‐ Sensitivity analysis by study quality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.36 [2.24, 8.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 50% reduction in seizure frequency ‐ ITT analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.71 [2.05, 3.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 50% reduction in seizure frequency ‐ Sensitivity analysis by patient characteristics (age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [2.09, 3.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 50% reduction in seizure frequency ‐ Sensitivity analysis by intervention (dosage) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.32 [2.51, 4.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 50% reduction in seizure frequency ‐ Best‐case analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.54 [2.67, 4.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 50% reduction in seizure frequency ‐ Worst‐case analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [1.54, 2.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Seizure freedom <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.67 [1.79, 7.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Treatment withdrawal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.37 [1.66, 3.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Ataxia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.29 [1.10, 4.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Difficulty with concentration/concentration impaired/concentration‐attention difficulties</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.81 [2.08, 29.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1385</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [1.07, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.08 [1.37, 3.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1092</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.67, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6 Nausea/vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>492</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.71, 3.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7 Paraesthesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.65 [1.58, 8.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.8 Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.44 [1.61, 3.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.9 Speech difficulties/language problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.37 [0.80, 14.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.10 Thinking abnormally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.70 [2.26, 14.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.11 Weight loss/decrease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.99 [1.82, 8.72]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Topiramate versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001417.pub4/references#CD001417-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001417.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD001417-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001417-note-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD001417-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD001417-note-0001">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD001417-note-0010">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001417\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001417\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001417\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001417\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001417\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001417\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001417\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001417\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001417\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001417\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001417\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001417\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001417\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001417\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001417\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001417\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001417\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001417\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001417.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001417.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001417.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001417.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001417.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728633996"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001417.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728634000"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001417.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec9454cdbf431',t:'MTc0MDcyODYzNC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 